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resumo 
 
 
Os lípidos podem modular o risco de desenvolver Adenocarcinoma Colo-
rectal Esporádico (ACE), uma vez que alterações nas vias do metabolismo 
e do transporte lipídico podem influenciar diretamente a absorção do 
colesterol e dos lípidos pelas células do cólon e indiretamente a síntese de 
espécies reativas de oxigénio (ERO) no reto, devido à acumulação de 
lípidos. O metabolismo lipídico é regulado por várias proteínas (APOA1, 
APOB, APOC3, APOE, CETP, NPY, PON1, PPARG) que podem 
influenciar o metabolismo e o transporte de lípidos. Tem sido reportados 
nestes genes, vários polimorfismos comuns (SNP) que podem alterar a 
sua função e/ ou a expressão, causando um desequilíbrio no metabolismo 
dos lípidos. Estas alterações genéticas podem influenciar o 
desenvolvimento de ACE, no entanto a maioria dos polimorfismos nunca 
foram estudados nesta patologia. Além disso, existem resultados 
contraditórios entre alguns dos polimorfismos e o risco de ACE. Deste 
modo, o objetivo deste estudo foi explorar e descrever o efeito dos 
polimorfismos comuns de genes associados ao metabolismo lipídico 
(APOA1 -75 G>A; APOB R3500Q; APOC3 C3175G, APOC3 T3206G; 
APOE Cys112/158Arg; CETP G279A, CETP R451Q; NPY Leu7Pro; PON1 
Q192R; PPARG Pro12Ala) no ACE e a sua relação com o risco de 
desenvolver ACE. 
A genotipagem dos polimorfismos comuns de genes associados ao 
metabolismo lipídico (APOA1 -75 G>A; APOB R3500Q; APOC3 C3175G, 
APOC3 T3206G; APOE Cys112/158Arg; CETP G279A, CETP R451Q; 
NPY Leu7Pro; PON1 Q192R; PPARG Pro12Ala) foi efetuada pela técnica 
de PCR-SSP, a partir de biópsias incluídas em parafina e fixadas em 
formol de 100 indivíduos saudáveis e de 68 indivíduos com ACE.  
Os genótipos mutantes APOA1 -75AA (32% vs 12%; p=0.001; OR=3.51; 
95% CI 1.59-7.72); APOB 3500AA (7% vs 0%; p=0.01); APOC3 3175GG 
(19% vs 2%; p=0.0002; OR=11.58; 95% CI 2.52-53.22), APOC3 3206GG 
(19% vs 0%; p<0.0001); CETP 279AA (12% vs 1%; p=0.003; OR=13.20; 
95% CI 1.61-108.17), CETP 451AA (16% vs 0%; p<0.0001); NPY 7CC 
(15% vs 0%; p<0.0001); PPARG 12GG (10% vs 0%; p=0.001); e o 
genótipo heterozigótico PON1 192AG (56% vs 22%; p<0.0001; OR=4.49; 
95% CI 2.29-8.80) demonstraram estar associados à prevalência de ACE. 
Enquanto, o haplótipo mutante APOE E4/E4 (0% vs 8%; p=0.02) mostrou 
ter um efeito protetor no ACE. Adicionalmente, também foram encontradas 
diferenças entre a prevalência e a localização tumoral (cólon ou reto) para 
os genótipos APOB 3500GA, APOC3 3206TG, CETP 279AA e para o 
alelo PPARG 12Ala. 
Estes resultados sugerem uma associação positiva entre a maioria dos 
polimorfismos genéticos comuns estudados envolvidos no metabolismo 
lipídico e a prevalência de ACE. A desregulação dos genes APOA1, 
APOB, APOC3, CETP, NPY, PON1, PPARG poderá estar associada com 
a diminuição dos níveis plasmáticos de colesterol e o aumento de ERO na 
mucosa do colon e do reto. Para além disso, estes resultados também 
suportam a hipótese de que o CCR esta relacionado com a diminuição da 
absorção intestinal e com o aumento da produção de ácidos biliares 
secundários. Adicionalmente, os polimorfismos estudados podem 
desempenhar um importante papel como biomarcadores de 
suscetibilidade para ACE. 
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abstract 
 
Lipids can modulate the risk of developing sporadic colorectal 
adenocarcinoma (SCA), since alterations into lipid metabolism and 
transport pathways influence directly cholesterol and lipids absorption by 
colonic cells and indirectly reactive oxygen species (ROS) synthesis in 
rectum cells due to lipid accumulation. Lipid metabolism is regulated by 
several proteins APOA1, APOB, APOC3, APOE, CETP, NPY, PON1 and 
PPARG that could influence both metabolism and transport processes. Is 
been reported that several common single-nucleotide polymorphisms 
(SNPs) in these genes could influence their function and/or expression, 
changing lipid metabolism balance. Thus, genetic changes in those genes 
can influence SCA development, once the majority of them were never 
studied in this disease. Furthermore, there are contradictory results 
between some studied polymorphisms and SCA risk. Thus, the aim of this 
study was to explore and describe lipid metabolism-associated genes 
common polymorphisms (APOA1 -75 G>A; APOB R3500Q; APOC3 
C3175G, APOC3 T3206G; APOE Cys112/158Arg; CETP G279A, CETP  
R451Q; NPY Leu7Pro; PON1 Q192R; PPARG Pro12Ala) status among 
SCA, and their relationship with SCA risk. 
Genotyping of common lipid metabolism genes polymorphisms (APOA1 -
75 G>A; APOB R3500Q; APOC3 C3175G, APOC3 T3206G; APOE 
Cys112/158Arg; CETP G279A, CETP R451Q; NPY Leu7Pro; PON1 
Q192R; PPARG Pro12Ala) were done by PCR-SSP techniques, from 
formalin-fixed and paraffin-embedded biopsies of 100 healthy individuals 
and 68 SCA subjects. 
Mutant genotypes of APOA1 -75AA (32% vs 12%; p=0.001; OR=3.51; 95% 
CI 1.59-7.72); APOB 3500AA (7% vs 0%; p=0.01); APOC3 3175GG (19% 
vs 2%; p=0.0002; OR=11.58; 95% CI 2.52-53.22), APOC3 3206GG (19% 
vs 0%; p<0.0001); CETP 279AA (12% vs 1%; p=0.003; OR=13.20; 95% CI 
1.61-108.17), CETP  451AA (16% vs 0%; p<0.0001); NPY 7CC (15% vs 
0%; p<0.0001); PPARG 12GG (10% vs 0%; p=0.001); and heterozygote 
genotype PON1 192AG (56% vs 22%; p<0.0001; OR=4.49; 95% CI 2.29-
8.80) were found associated with SCA prevalence. While, APOE E4/E4 
(0% vs 8%; p=0.02) mutant haplotype seemed to have a protective effect 
on SCA. Moreover, it also been founded differences between APOB 
3500GA, APOC3 3206TG, CETP 279AA genotypes and PPARG 12Ala 
allele prevalence and tissue localization (colon vs rectum). 
These findings suggest a positive association between most of common 
lipid metabolism genes polymorphisms studied and SCA prevalence. 
Dysregulation of APOA1, APOB, APOC3, CETP, NPY, PON1 and PPARG 
genes could be associated with lower cholesterol plasma levels and 
increase ROS among colon and rectum mucosa. Furthermore, these 
results also support the hypothesis that CRC is related with intestinal lipid 
absorption decrease and secondary bile acids production increase. 
Moreover, the polymorphisms studied may play an important role as 
biomarkers to SCA susceptibility. 
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1. Introduction 
 
Colorectal cancer (CRC) is the fourth most common cancer cause of death 
worldwide.1 CRC is a serious health problem, a challenge for research, and a model for 
studying the molecular mechanisms involved in its development.2 This pathology 
comprehends to types of tissue structures colon (constituted by four sections, such as, 
ascending colon located on the right side, transverse colon, descending colon located on 
the left side and sigmoid colon) and rectum.3 Colon mucosa has multiple tubular 
invaginations called “crypts of Lieberkuhn”, that are wide, deep, and numerous, along the 
surface of its epithelium and in which the regeneration of the epithelium takes place. 
Because of its biological nature, the colon has a high level of cellular regeneration and a 
physical, chemical, and biological nature, which increases the possibility of developing 
several pathologies, including cancer.2 Rectum is located between sigmoid colon and anal 
canal, it has among 12 to 16 cm long and can be subdivided in three parts: upper rectum, 
middle rectum and lower rectum. Histologically is identical with colon, constituted by 
mucosa, submucosa, muscularis and serosa. Mucosa is constituted by typical intestinal 
epithelium. At anal transitional zone the columnar epithelium flattens becomes a 
stratified squamous non-keratinized epithelium. Submucosa contains loose connective 
tissue with blood vessels, lymph follicles and the Meissner's plexus. Lastly, muscularis has 
the typical inner circular and outer longitudinal musculature between which the 
Auerbach’s plexus.4 
CRC development involves one or more genetically altered cells and requires many 
years to progress5, with a multistep process that affords nutrients an opportunity to 
modify the evolution of the disease. Many different dietary nutrients, such as lipids, 
contact epithelial cells in the colonic crypts both from the lumenal contents of the colon 
and from the basolateral epithelial cell membranes, thereby influencing developmental 
processes in both normal and transformed colonic epithelial cells.6 On other hand, rectum 
tissues are in contact with diet waste, including lipids that are not transported into blood 
stream. There are vary genetic and environmental factors involved in CRC development, 
namely, genes involved in metabolic processes, including lipid metabolism.7,8 There are 
many authors that referred an association between CRC, low cholesterol intestinal 
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absorption9,10,11  and high secondary bile acids excretion thru feces12. Additionally, single-
nucleotide polymorphisms (SNP’S) in lipid metabolism genes also are determinants 
potentials involved in progression of CRC, being this topic more development in 
environmental and genetic factors.8 
 
1.1. Epidemiology of colorectal cancer 
1.1.1. Incidence and mortality 
 
Every year more than 1,2 million patients are diagnosed with CRC , and more 600 
000 die in the world with CRC.1  CRC represents 12.9% of all newly diagnosed cancers and 
is responsible for 12.2% of all cancer deaths, in Europe.13  CRC is the third most common 
cancer in men (746,000 cases, 10.0% of the total) and the second in woman (614,000 
cases, 9.2% of the total) worldwide. However, CRC is not uniformly common throughout 
the world, about 55% of the cases occur in more developed countries (Figure 1.A). But, its 
mortality is higher in less developed regions because medical resources privation (Figure 
1.A).14   
In Portugal, CRC incidence also has been increased in recent decades; it presents a 
large variety, depending on the geographical region. According to 2012 data, the CRC is 
the cancer with higher incidence and mortality among both genders (Figure 1.B).14 
Furthermore, deaths by CRC increased 3% per year between 2000 and 2005 and the 
overall survival rates at 1, 3 and 5 years are estimated at 73%, 55% and 46%, 
respectively.13 
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Figure 1. Epidemiology. (A) Colorectal cancer incidence and mortality to both genres in the 
worldwide. (B) News cases and deaths of different cancers in Portugal.14 
 
Generally, according to the Globocan 2012 data, in Portugal, Europe and 
worldwide there is a high incidence and mortality for CRC, it can be stated that 
approximately half of those who diagnose this tumour die. Also, is estimated that the 
prevalence of CRC in both genders should duplicate in a five years range (Table 1).15 
 
Table 1. Estimated incidence, mortality and 5-year prevalence for colorectal cancer, in World, 
Europe and Portugal to men and women.15 
 
 Region Gender 
Number of cases 
Incidence Mortality 5-year prevalence 
Colorectal 
cancer 
World 
Men 746298 373639 1953431 
Women 614304 320294 1590151 
Europe 
Men 241813 113246 656384 
Women 205323 101620 547559 
Portugal 
Men 4209 2240 11581 
Women 2920 1557 8032 
 
A B 
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The rapid increases in the previously low-risk countries, such as Spain and several 
countries in eastern Europe and east Asia, have been noted, which have been ascribed to 
changes in dietary patterns and risk factors towards a so-called western lifestyle.16,17 
However, in the USA and several other high income countries, incidence has stabilized or 
started to decrease, probably because of increased use of sigmoidoscopy and 
colonoscopy with polypectomy.3,18,19,20 In several high-income countries and countries of 
east Asia and eastern Europe, mortality has been decreasing since the 1980s, probably 
because of improved early detection and treatment.18 Nevertheless, rates are still 
increasing in countries or areas with poor health-care resources, including countries in 
Central and South America21 and rural areas in China22. 
The increase of CRC cases number in the last thirty years is strongly linked to 
changes in lifestyle and exposure to carcinogens. The gradual abandonment of the 
Mediterranean diet23, increased caloric intake, increased intake of animal fats24 and red 
meats25, increased obesity and sedentary lifestyle26, as well as tobacco consumption are 
strong contributors to the increase in CRC incidence.19 
 
1.1.2. Etiology 
 
There are three different types of CRC development that can be distinguished: 
sporadic; family; and hereditary form. About 60-85% of CRC cases are sporadic type that 
occurs in patients with advanced ages. Sporadic cancers are caused by genetic 
abnormalities in tumour suppressor genes and oncogenes that give cells an evolutionary 
advantage over their neighbors. However, hereditary and familial CRC forms, are 
responsible for 5-10% and 10-30% of the cases, respectively.2 Hereditary non-polyposis 
colorectal cancer (Lynch Syndrome) is the most common form of hereditary CRC. It is 
inherited in autosomal dominant fashion, its clinical consequences develop from germline 
mutations in mismatch repair (MMR) genes, where occurs the inactivation of the repair 
system.27 Other hereditary syndrome, is familiar adenomatous polyposis (FAP) that is 
characterized by numerous of adenomatous colorectal polyps. FAP is an autosomal 
dominant hereditary cancer syndrome caused by a germline mutation in the APC gene 
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(adenomatous polyposis coli), being the first molecular event in the progress of sporadic 
colorectal adenocarcinoma.28,29,30 
These CRC forms can develop through different genetic pathways. The 
chromosomal instability (CIN) pathway occurs in 80-85% of the CRC (Figure 2), known as 
the adenoma-carcinoma sequence.27,31,32,33 In inherited and sporadic tumours it has been 
demonstrated several alterations in specific genes, involved acquisition of a new or 
increased oncogenes function and tumour suppressor genes function loss. The genetic 
changes include tumour suppressor genes APC (chromosome region 5q21) and TP53 
(chromosome region 17p13) function loss, proto-oncogenes (K-ras) activation and 
heterozygosity for the long arm of chromosome 18q (DCC, SMAD2, SMAD4) LOH 
loss.5,34,35,36  Beyond this, aneuploidy, amplifications, and translocations are also common 
in these tumours. Other genetic pathway, present in 15% of CRC cases, is microsatellite 
instability (MSI) characterized by DNA mismatch repair (MMR) system proficiency loss 
(Figure 2).27  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic classification of colorectal cancers.27 
 
1.2. Histological classification 
 
More than 90% of CRC are adenocarcinoma's; its origin comes from colorectal 
mucosa epithelial cells. Conventional adenocarcinoma is characterized by glandular 
formation, which is the basis for histologic tumour grading. In well differentiated 
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adenocarcinoma's (Stage I) >95% of tumours are gland forming. Moderately 
differentiated adenocarcinoma's (Stage II) show 50-95% gland formation. Poorly 
differentiated adenocarcinoma's (Stage III) are mostly solid with <50% gland formation. In 
general, most colorectal adenocarcinoma's (±70%) are diagnosed as moderately 
differentiated. Well and poorly differentiated adenocarcinoma's account for 10% and 
20%, respectively. Invasive colorectal adenocarcinoma's may be seen dysplasia in 
adjacent mucosa. Cells with high-grade dysplasia exhibit rounded nuclei, coarse 
chromatin, prominent nucleoli, and loss of nuclear polarity with nuclei no longer being 
oriented perpendicular to the basement membrane.37,38 Histological classification of CRC 
is based upon the most recent classification version (7th edition, 2012) according to 
World Health Organization (WHO) (Table 2).39 
 
Table 2. Histological classification according to the 7th version (2012) from World Health 
Organization (WHO).39  
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1.3. Environmental and genetic risk factors 
Development and progression of CRC could be influenced by several risk factors, 
namely, genetic and environmental factors. These factors include advanced age; family 
and medical histories of benign adenomatous polyps and inflammatory bowel diseases; 
low vegetables and fruits intake; high red and processed meat intake25; smoking habits; 
excessive alcohol consumption; physical inactivity; obesity26; and diabetes.1,3,19,24 
Furthermore, genetic alterations in tumour suppressor genes and oncogenes that are 
responsible for MSI; defects in the DNA mismatch repair; mutations; and SNPs in genes 
involved in the metabolic pathways also have been implicated in CRC.40 Individual genetic 
variants arrangements could affect sporadic CRC associated risk when combined with 
others environmental factors, especially with diet patterns.41  
Diets with high fat-animal ingestions can influence highly carcinogenesis initial 
phases, appearing to be an important risk factor for CRC.6 Genome-wide association 
studies (GWAS) have identified SNPs in genes involved in the regulation of lipid 
biosynthesis, transport, and metabolism42, being some potentials susceptibility factors to 
CRC. SNPs are mutations with minor allele frequency of greater than 1% in at least one 
population.43 Those mutations are characterized by single nucleotide base pair insertions, 
deletion, or substitutions. SNPs location is also important, if SNP is in an intron, it may 
change the binding ability of transcription factors to the SNP area, thus influencing gene 
expression. On the other hand, if the SNP is located in the exon coding region it may 
affect the structure of the translated protein, which may affect its sensitivity to upstream 
signal or effectiveness in downstream function.40 Interestingly, some SNPs are associated 
with specific ethnic groups or geographic ancestral subpopulations. Effects of lipid 
metabolism genes polymorphisms associated with CRC risk can be mediated and modified 
through their implication in energy balance, dietary patterns, obesity or physical 
activity.44  
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1.4. Lipid metabolism genes and CRC 
Cancer is characterized by uncontrolled cell growth with increased proliferation, 
decreased apoptosis and improves migrating behavior of cells by promoting their ability 
to invade adjacent tissues and/or metastasize to non-adjacent organs and tissues. Cell 
proliferation requires duplication of all macromolecular components during each cell 
division.45 Aberrant lipid metabolism is a key feature of cancer cells development since 
cell proliferation requires increased lipid biosynthesis, and lipid catabolism produces 
bioactive molecules that act as signal molecules to regulate cancer metastasis.45 Lipids are 
hydrophobic or amphipathic small molecules, which are insoluble in water but soluble in 
nonpolar solvents. These molecules form plasma membranes enabling the maintenance 
of intracellular biological events and the response to changes in the extracellular medium. 
In living cells, lipids play essential functions, allowing the support of cellular structure, 
energy supply and participation in cell signaling.46 Lipid metabolism involves the 
activation and regulation of multiple signaling pathways. Thus, it enables various 
connection signaling pathways involved in cell growth regulation, proliferation, 
differentiation, survival, apoptosis, inflammation, motility and membrane homeostasis. In 
addition, it can change membrane composition and permeability causing disease 
development and progression, namely CRC. Three classical lipids (fatty acids, 
phospholipids and cholesterol) are dramatically increased and actively biosynthesized in 
cancer cells. Several evidences show that fatty acid synthase expression and activity are 
extremely low in nearly all nonmalignant adult tissues, whereas it is significantly up-
regulated in solid cancers.45 
Cholesterol is an essential constituent of cell membranes. It is the most frequent 
steroid in the organism, playing a physiological role.  Cholesterol and triglycerides are 
insoluble in water molecules and are transported in association with proteins. 
Lipoproteins are complex particles with a central core containing cholesterol esters and 
triglycerides, a second layer is composed by free cholesterol and phospholipids delimited 
by apolipoproteins (Figure 3). Plasma lipoproteins are classified into seven classes which 
are based on their size, lipid composition and apolipoprotein: chylomicrons (CM) and the 
remaining chylomicrons, VLDL (very low density lipoprotein), IDL (Intermediary density 
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lipoprotein), LDL (Low Density Lipoprotein), HDL (High Density Lipoprotein). VLDL, IDL and 
LDL are pro-atherogenic, while HDL is anti-atherogenic.47 
 
 
 
 
Figure 3. Schematic of high density lipoproteins (HDL) and low density lipoproteins (LDL) 
structure. Apo indicates apolipoprotein.48 
 
 
Lipoproteins metabolism is divided in three pathways: exogenous diet associated 
(Figure 4); endogenous liver associated (Figure 5); and reverse cholesterol transport 
pathway (Figure 6).49 Lipoproteins play a central role in intake-lipid absorption and 
transport through the small intestine; in lipids transport from liver to peripheral tissues; 
and in lipids transport from peripheral tissues to liver and intestine (reverse transport). 
Exogenous pathway (Figure 4) begins with diet-lipids incorporation into chylomicrons on 
intestine. Thru circulation, triglyceride are transported in chylomicrons into muscles and 
adipose tissue here lipoprotein lipase (LPL) metabolize them forming chylomicron 
remnants, used as energy storage. Cholesterol (chylomicron remnants) is then carried 
into liver (where it can be used for VLDL and bile acids formation), or back to intestine 
through bile secretion.47 
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Figure 4. Schematic representation of exogenous cholesterol transport pathway.47 
 
Endogenous pathway (Figure 5) begins at liver with VLDL formation. Triglycerides 
included in VLDL are metabolized and transported into muscle and adipose tissue. In 
circulation, lipoprotein lipase transforms VLDL into IDL, which is metabolized into LDL. LDL 
is then absorbed by its receptor in several tissues, including liver, being the predominant 
uptake site.47 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of endogenous cholesterol transport pathway.47 
  
Finally, reverse cholesterol transport (Figure 6) begins with HDL formation on liver and 
intestine. The small particles can acquire HDL cholesterol and phospholipids which are 
expelled out of cells, a process mediated by ATP-binding cassette transporter A1 (ABCA1) 
resulting in mature HDL formation. Mature HDL can get cholesterol from cells bias ATP-
Common lipid metabolism genes polymorphisms and SCA risk | Pandeirada R. 2015   32  
 
binding cassette transporter G1 (ABCG1), scavenger receptor class B1 (SR-B1), or passive 
diffusion. Then HDL transports cholesterol directly into liver through interaction with 
hepatic SR-B1; or indirectly through VLDL or LDL cholesterol transfer by a process that is 
facilitated by CETP. 47  
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of reverse cholesterol transport pathway.47 
 
Apolipoproteins play a structural level function; they act as ligands for receptors 
and drive lipoproteins formation. In addition to those functions, apolipoproteins also 
activate and inhibit lipoprotein metabolism enzymes. Thus, they control lipoprotein 
transport and metabolism, and their dysregulation has been identified in several 
pathologies. Major apolipoproteins involved in lipid metabolism are APOA1, APOB, 
APOC3 and APOE.50 In addition to these proteins, also CETP51, NPY52, PON153 and PPARG54 
proteins play an essential role in lipid transport and metabolism. As described in the 
literature genes encoding these proteins contains polymorphic variant associated with 
various metabolic diseases.55,56,57,58,59,60,61,62,63  
1.4.1. Apolipoprotein A (APOA1) 
 
Apolipoprotein A1 (APOA1) is a 28-kD protein with 243 amino acid residues, being 
considered the major surface apoprotein of HDL-C in plasma.64,65 This molecule is 
produced primarily in liver (80%) and small intestine (10%)66, and includes more than 30% 
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of HDL mass and 70% of HDL protein.67 APOA1 functions as a cofactor of lecithin-
cholesterol acyltransferase (LCAT) and it is a fundamental element of reverse cholesterol 
transport process.68 Several studies have shown that the APOA1 gene displays a key role 
in tumour progress, inflammation, angiogenesis, invasion and metastasis.69 The increased 
APOA1 levels in patients with adenocarcinomas were associated with tumour progression 
and lymphatic invasion.70 According to recent findings APOA1 may be considered as a 
potential diagnosis and prognostics marker in several cancer types.69  
APOA1 gene located on chromosome 11p23.24 (Figure 7) and have a common 
polymorphism in promotor region, APOA1 -75 G>A (rs670).71,72 In this variant occurs the 
substitution of guanine (G) by adenine (A), that is associated with HDL-C concentrations 
and raised serum APOA1. This particular polymorphism occurs with an allele frequency of 
about 30% in the population general, being 15-20% among Caucasian population.73 Thus, 
APOA1 -75A individuals have higher levels this molecule and/or HDL cholesterol than 
those that have the wild type allele.65,74 APOA1 -75 promoter changes the answers of 
small and large HDL particle distribution to exercise training.67 Some recent studies 
reported and association between different HDL plasma levels and cancer susceptibility, 
including CRC.75,76  
 
Figure 7. Cytogenetic localization of APOA1 gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=APOA1&keywords=APOA1) 
 
1.4.2. Apolipoprotein B (APOB) 
Apolipoprotein B (APOB) is a key protein in the lipid transport and metabolism, 
such as plasma triglyceride (TG) and cholesterol.77 Moreover, it is the main apolipoprotein 
of chylomicrons, as well as VLDL, IDL, LDL particles.78 APOB is used as ligand for LDL 
recognition and catabolism, maintaining LDL particles integrity and LDL-C plasma levels 
control through receptors binding.79 APOB is produced primarily in hepatocytes and 
enterocytes. This molecule is present in lipoprotein particles and it presents two isoforms 
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in humans, APOB-100 and APOB-48. APOB-100, full-length protein containing  4536 
amino acids residues, being an indispensable structural protein for VLDL formation and 
secretion, APOB-100 is expressed primarily in liver.77 The interactions among dietary and 
APOB genetic variants could affect individual’s plasma lipid levels and body weight.80  
APOB gene is located on short arm of chromosome 2p24.1 (Figure 8), and is 
composed by 28 introns and 29 exons.81 Some studies demonstrate an association 
between the APOB SNPs and hypercholesterolemia in Spanish56 and Hungarian82   
subjects. It has been reported that point mutations in APOB receptor-binding zone can 
disrupt binding and impair LDL removal from circulating. LDL receptor pathway regulates 
cholesterol plasma concentration. Thus, defects that occur in ligand (APOB) or receptor 
(LDL-R) could increase LDL plasma concentrations, resulting from inefficient clearance of 
LDL particles by its receptor. Consequently, it can lead to LDL particles accumulation in 
circulation that could increase the risk of pathologies related to cholesterol imbalance. An 
example of these mutations, is the APOB R3500Q variant (rs5742904)83, characterized by 
a G to A nucleotide transition, in exon 6 of APOB gene which origin an amino acid 
substitution (glutamine for arginine) at position 3500. 81,84,85 In Caucasian population the 
mutation frequency is very low, 1:500 to 1:700, but its frequency is much higher in 
several cholesterol dependent disorders, including cardiovascular and cancer diseases.86 
 
 
Figure 8. Cytogenetic localization of APOB gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=APOB&keywords=APOB) 
 
 
1.4.3. Apolipoprotein C3 (APOC3) 
Apolipoprotein C3 (APOC3) is a major component of VLDL and chylomicrons, and it 
is associated with triglyceride rich lipoproteins (TRLs) levels.87 This molecule is 
synthesized by the liver and intestine.88 APOC3 is an inhibitor of lipoprotein lipase and 
decreases liver´s absorption of TRL and its remnants (Figure 9). Several studies have 
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demonstrated that an increase of APOC3 plasma levels is strongly correlated with high 
triglycerides blood levels.57  
 
 
 
 
 
 
 
 
 
 
Figure 9. Representation APOC3 effects in lipoprotein metabolism pathways. APOC3 can 
modulate enzymes that are involved in cholesterol transport from extrahepatic tissues to the 
liver. APOC3 inhibits (↓) LCAT activity, VLDL TGs clearance and TRLs lipolysis. Furthermore, 
APOC3 also stimulates (↑) CETP activity88 
 
 
APOC3 gene is located in the long arm of chromosome 11q23 (Figure 10). This 
gene is about 311kb length and it has 4 exons and 3 introns. Two common 
polymorphisms in APOC3 have been reported, C3175G (rs5128) and T3206G (rs4225), 
characterized by a C to G and T to G substitution, respectively. 57,89 A study performed in 
Han Chinese males of APOC3 C3175G variant demonstrated that triglyceride plasma level 
on mutant homozygous (GG genotype) carriers were higher than APOC3 3175CG 
genotype carriers and APOC3 3175CG genotype has higher triglyceride plasma levels than 
CC genotypes (wild-type). These results suggest that G APOC3 form may influence TG 
lipase synthesis. Although 3175G variant is associated with total cholesterol and LDL 
levels increase, APOC3 3206G mutant allele seems to have an inverse effect. A study 
demonstrated that APOC3 3175G mutation allele represents a risk factor and APOC3 
3206G variant is a benefic factor for cardiovascular diseases, since it is associated with 
triglycerides blood levels reduction. 57 Nevertheless their role in CRC is not clear. 
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Figure 10. Cytogenetic localization of APOC3 gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=APOC3&keywords=APOC3) 
 
1.4.4. Apolipoprotein E (APOE) 
Apolipoprotein (APOE) is a glycoprotein with a molecular mass of 34 kDa of 299 
amino acids.90 This molecule is crucial for cholesterol transport, lipid metabolism and 
synthesis.91 In addition, this protein has shown to have an important role in lipid 
metabolism, angiogenesis, tumour cell growth, metastasis, antioxidant and immune 
activities.41 Thus, all these features make APOE a potential candidate in carcinogenesis 
development. Also, it has a significant metabolic function in the transport and lipids 
deliver from one tissue or cell type to another, it is synthesized and secreted by many 
tissues, liver, small intestine (only secrete), brain, skin, and tissue macrophages 
throughout the body. Furthermore, APOE is a component of VLDL particles.90  
APOE gene is localized on long arm of chromosome 19q13.2 (Figure 11) and is 
constituted for four exons and three introns.92 Some studies had showed that APOE 
exhibit multiple isoforms: E2, E3 and E4. Those variants combine in six different 
genotypes: three homozygous phenotypes (E2/2, E3/3, and E4/4) and three heterozygous 
phenotypes (E3/2, E4/2, and E4/3).90 All alleles are different in primary structure at two 
sites: residues 112 (rs429358) and 158 (rs7412).41 APOE*3 has a cysteine at residue 112 
and arginine at residue 158, while APOE*4 has 2 arginine and APOE*2 has 2 cysteine in 
both 158/112 residues. APOE*2 and APOE*4 is associated with increased and decrease 
APOE levels, respectively.90 The presence of different APOE variants influences the 
enterohepatic metabolism of cholesterol and bile acids, which promote colorectal 
carcinogenesis.58,93,94 A study carried in Finland showed that the presence of APOE E4 
allele could provide protection from adenoma and carcinoma development on proximal 
colon, due to reduced bile acids production.93 On the other hand, some studies 
demonstrate that women with high triglycerides levels and with one or two copies of 
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APOE E4 allele had four times higher risk of developing breast cancer when compared 
with women with low triglyceride levels.91,95Nevertheless, E2, E3 and E4 isoforms are 
associated with several cancers predisposition96,97, including colorectal cancer93, being 
APOE E3 allele the most predominant form98.  
 
Figure 11. Cytogenetic localization of APOE gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=APOE&keywords=APOE) 
 
 
1.4.5. Cholesterol ester transfer protein (CETP) 
Cholesterol ester transfer protein (CETP) has an important role in HDL plasma 
levels regulation. CETP helps in cholesteryl ester and triglyceride transfer and exchange 
between HDL, LDL and VLDL. Moreover, it also plays a role in liver’s cholesterol ester 
uptake and in plasma lipoproteins quantity and quality control.51,99 
 CETP gene is composed by 16 exons59 and is located in 16q13 chromosome (Figure 
12). Findings have described two genetic variants, involved in several diseases, CETP 
G279A (rs708272) and CETP R451Q (rs1800777).100 CETP G279A variant has been 
identified as an essential cholesterol concentration regulator within HDL fraction. CETP  
279G allele (allele B1) is responsible for higher CETP activity and lower cholesterol 
concentration in HDL fraction. While, the presence of CETP 279A allele (allele B2) is 
related with lower CETP activity and higher HDL values.60 On other hand, there is R451Q 
mutation, in which occurs a G to A substitution, modifying arginine (451) to glutamine in 
CETP protein.99 CETP 451Q mutant allele appears in low frequency in general population, 
about 2-7%, and has been associated with higher CETP activity and lower HDL-C levels. 
59,101  
 
Common lipid metabolism genes polymorphisms and SCA risk | Pandeirada R. 2015   38  
 
 
Figure 12. Cytogenetic localization of CETP gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CETP&keywords=CETP) 
 
1.4.6. Neuropeptide Y (NPY) 
Neuropeptide Y (NPY) is a neurotransmitter present in central and peripheral 
nervous system, several peripheral organs, and plasma. This plays an important role in 
glucose-stimulated insulin secretion inhibition, renal blood flow regulation and is 
implicated in control and management feeding behaviors and food intake.102 NPY has the 
ability to induce obesity; this propriety was already confirmed in animal models.103 This 
fact, results in an increase of plasma insulin concentration. Findings indicate that NPY 
gene is a prime candidate gene for obesity.104 Moreover, also have been demonstrated 
that NPY promotes proliferation and vascularization, stimulate migration, formation of 
capillary tubes, development of blood vessels and it has many immunomodulatory 
functions, including modulates of the functions of macrophages.105,106  
NPY gene is located in chromosome 7p15.1 (Figure 13) and has a SNP, NPY  
Leu7Pro (rs16139)107, associated with NPY process, levels growth hormone secretion and 
serum cholesterol and triglyceride levels.  In the NPY Leu7Pro SNP occurs a thymidine to 
cytosine nucleotide substitution (T1128C) in a coding region of NPY gene, interfering with 
signal pathway.102 This mutation is linked with the increase of the NPY synthesis and 
secretion levels being more frequent in Caucasian population (6% to 15%).106 Also, higher 
serum total cholesterol and lipid levels, and increased body mass index (BMI) are related 
with the NPY Leu7Pro polymorphism.61,108,109,110 Nevertheless, its implication on CRC risk 
is not yet clarified, although there is a strong association between NPY and obesity, other 
cancer types and colorectal predisposal.111,112 
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Figure 13. Cytogenetic localization of NPY gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=NPY&keywords=NPY) 
 
1.4.7. Paraoxonase 1 (PON1) 
Paraoxonase 1 (PON1) is a protein with 354 amino acids and a molecular mass of 
43 KDa. This enzyme is synthesized mainly in liver and secreted into blood, where it is 
associated exclusively with HDL (Figure 14).113,114 In animal models and human HDLs are 
major carriers of plasma lipid hydroperoxides (LOOHs). Moreover, PON1 enzyme has 
several roles such as protection against oxidative damage and lipid peroxidation, helps in 
the innate immunity, reactive molecules detoxification, drugs bioactivation, endoplasmic 
reticulum stress modulation and cell proliferation/ apoptosis regulation.115 Some studies 
confirmed that PON1 prevents oxidized LDL formation and inactivates LDL-derived 
oxidized phospholipids once they are formed; furthermore it also protects phospholipids 
in HDL from oxidation.116 A diet rich in fat and cholesterol modulate PON1 activity.117  
 
 
 
 
 
 
 
 
 
 
Figure 14. Effect of dietary components on regulation of PON1 activity and its interaction with 
genetic factors.117 
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PON1 gene is located in chromosome 7q21.3 (Figure 15) and is coded by nine 
exons. This gene has a polymorphism in the coding region, involved in various diseases 
and conditions, PON1 Q192R (rs662;A>G), resulting in Glutamine (Q) to Arginine (R) 
substitution 192 codon, leading to differences in hydrolytic activity towards paraoxon.113 
Like other genes ethnicity and diseases can affect its distribution frequencies. Patients 
with CRC exhibit low PON1 plasma, high lipid peroxide and LOOH levels. This suggests a 
possible involvement of oxidative stress and PON1 variants in CRC.118,119,62,120  
 
 
Figure 15. Cytogenetic localization of PON1 gene. (Adapted from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=PON&keywords=PON) 
 
1.4.8. Peroxisome proliferator-activated receptor gamma (PPARG) 
Peroxisome proliferator-activated receptor gamma (PPARG) belongs to a group of 
nuclear hormone receptor that behaves as transcription factors that regulate genes 
expression. When PPARG interacts with the specific ligands is translocated into the 
nucleus, changes its structure and regulates gene transcription. PPARG plays an essential 
role in lipid metabolism, adipocytes differentiation and immune regulation. There are 
three isoforms of PPARG occurring by alternative splicing and promotors: PPARG1; 
PPARG2; and PPARG3.121  
PPARG gene is located in 3p25.1 chromosome (Figure 16). A common variant has 
been found in PPARG, characterized by a C to G substitution at exon 2. This alteration 
change Proline to Alanine at codon 12 (Pro12Ala) of PPARG gene, which reduces its 
promoter affinity and transcriptional activity. Some studies have shown that PPARG loss-
of-function is associated with the increased risk of CRC.63,122 High activity of PPARG 
prevents the S-phase entry into the cell cycle, inhibiting the proliferation of malignant 
cells. It also has been shown that the nuclear factor kappa B (NF-B) and signal transducer 
and activator of transcription 3 (STAT3) inflammation pathways and cell growth could be 
inhibited by ligand activation of PPARG, allowing apoptosis and promote differentiation in 
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colon, breast and prostate cell lines.121,123 However, other studies carried out in mice with 
a high fat diet, shows that the activation of PPARG is associated with the CRC 
progression.124  
PPARG Pro12Ala (rs1801282)125 substitution is associated with reduced 
transactivation activity. High activation of PPARG can lead to development of tumours by 
inhibition of expression of prostanoid and integrin receptors, by reducing the expression 
of fibronectin and by inhibiting angiogenic production and inflammatory signals. 
Furthermore, PPARG ligands may increase tumour suppressors, such as PTEN 
(Phosphatase and tensin homolog) and p21, expression and/or activity.125 Some works 
suggest that the presence of the PPARG 12Ala allele, which is associated with reduced 
PPARG activity, might decrease colon cancer susceptibility.126 PPARG 12Ala was 
recognized to be associated with increased tissue sensitivity to insulin, a decrease in 
insulin plasma level, reduced release of free fatty acids by adipocytes, which may 
indirectly explain the lower colon cancer risk in subjects with this polymorphism.125 
Nevertheless its role in rectum cancer is not entirely clarified, seeming to have an 
opposite role in this type of tissue.  
 
 
Figure 16. Cytogenetic localization of PPARG gene. (Adapted from: 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=PPARG&keywords=PPARG) 
 
1.5 . Lipid transport and metabolism genes in Sporadic Colorectal 
Cancer (SCA) 
 
Gene variants associated with various environmental and dietary factors can affect 
sporadic colorectal cancer risk. High fat diets are a fundamental risk factor for CRC 
development127, and its influence appears to be stronger during post-initiation phases of 
carcinogenesis.6 Accordingly, molecular mechanisms and pathways that could interfere in 
lipid transport and metabolism should be considered as a potential risk modulators for 
this neoplasia. Multiple genetic determinants, comprising several gene polymorphisms, 
Common lipid metabolism genes polymorphisms and SCA risk | Pandeirada R. 2015   42  
 
involved in lipid metabolism regulation, as well as, in lipid transport had been reported as 
risk factors for CRC.8 APOA1, APOB, APOC3, APOE, CETP, NPY, PPARG and PON1 genes 
have a considerable role in lipid transport regulation and metabolism, therefore 
numerous studies which including their common polymorphic variants demonstrate that 
they could affect these pathways.55,56,57,58,59,60,61,62,63 However, for most of the studied 
SNPs is unowned their association and influence on CRC.  
Most authors recognize that a high fat diet is essential to raise the CRC risk by 
increasing bile acids secretion.128,129,130 This increased secretion has a non-specific irritant 
effect on colonic and rectal mucosa since it stimulates secondary bile acids formation. 
This effect can cause damage in intestinal epithelium bias oxidative stress and lipid 
peroxidation, stimulating endogenous mutations and increasing tumour proliferation. 
128,129,130,131  
Since APOA1, APOB, APOC3, APOE, CETP, NPY, PPARG and PON1 polymorphisms 
are responsible for different enzymatic activities among individuals, that consequently 
control the bile acids metabolism, and also because the role of these polymorphisms in 
SCA pathological progression has not been fully explained. Our study aims to clarify these 
issues by coming across the relationship between APOA1, APOB, APOC3, APOE, CETP, 
NPY, PPARG and PON1 genotypes and SCA, as well as their interaction with other 
molecules. 
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Chapter II 
Material and Methods 
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2. Materials and methods 
2.1. Biological samples 
 
This study included 68 SCA biopsies samples formalin-fixed and paraffin-
embedded (FFPE) (mean age of 73.7 +/-10.7 years; 75% men and 25% women), previously 
selected. As control group were used 100 biopsies of healthy subjects, from screening 
(mean age of 72.7 +/-8.9 years; 79% men and 21% women) (Table 3). Biopsies were 
collected from 2009 to 2011 from the archives of Institute of Anatomical Pathology, 
Faculty of Medicine of the University of Coimbra. SCA samples were clinically identified as 
belonging to colon (31 samples) and rectum (37 samples) carcinomas and were selected 
according to the malignant cells availability with at least 60 malignant cells. SCA cases 
were classified according to WHO criteria39 (Table 2), being all samples used here 
classified as well differentiated adenocarcinoma (Figure 17). This study was supported 
and approved by local ethics committee (CIMAGO - Faculty of Medicine of the University 
of Coimbra, Coimbra, Portugal). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. (A), (B) Histologic image of normal colonic mucosa: 40x HE (Haematoxylin-eosin), 200x 
HE; (C), (D) Histological image of well differentiated sporadic colorectal adenocarcinoma 
(According to WHO criteria). 100x HE; 200x HE. Images from IAP-FMUC. 
B A 
D C 
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Table 3. Clinical pathological data SCA and controls. 
 
         Tumour localization 
   Distribution Age Colon Rectum 
Total 
 Gender % Mean Stand. Dev. n % n % 
SCA 
Male 75 
73.7 10.7 
25 81 26 70 51 
Female 25 6 19 11 30 17 
Total 100   31 100 37 100 68 
Controls 
Male 79 
72.7 8.9 
 
Female 21 
Total 100        
 
2.2. DNA extraction 
 
DNA genomic isolation from biopsies were made according to the extraction 
protocol from NZY Tissue gDNA Isolation Kit (NZYTech, Lisbon, Portugal), after 
microdissection of the normal and tumour tissue (5 to 10 dissections of 10µm of thickness 
to each sample). Samples were prepared by adding 1 ml of xylene to each tube to paraffin 
removal. After centrifugation at 11,000xg for 3 min, supernatant was discarded and 
samples were washed with 1ml of ethanol (96%-100%), repeating the centrifugation step. 
Next to this process, cellular membrane lysis were done by adding 25 µl of Proteinase K 
and 180 µl of Buffer NT1 into each sample, and mixed thoroughly by vortex and incubated 
at 56 ˚C overnight. Afterwards, 210 µl of ethanol (96%-100%) was load to the samples, 
and mixed immediately by vortex. In a next step occurred the DNA binding and the 
mixture was transferred to into a NZYSpin Tissue Column placed in a 2 ml collection tube, 
and centrifuged for 1 min at > 11,000xg. After this, the flows-through were discarded and 
the columns were placed back into a new collection tube. Washing silica membrane steps 
are essential to impurities elimination and were done by adding 500 µL of Buffer NW1 to 
the columns, centrifuged (for 1 min at > 11,000xg) and the flows-through were discarded. 
After this, the same procedure was repeated using 600 µL of Buffer NW2. Then, to dry the 
silica membrane the column was centrifuged for 2 min at > 11,000xg. Finally, the columns 
were placed into a clean microcentrifuge tube and add 100 µl of sterile water, incubated 
1 min at room temperature and centrifuged at > 11,000xg for 2 min to elute DNAs. 
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Genomic DNA samples were stored at -20 ˚C following of purity and concentration 
determination of all DNA samples, by spectrophotometry, applying a wavelength of 
260/280nm. 
2.2.1. Analysis of concentration and quality of the extracted DNA 
 
DNA samples were quantified in a spectrophotometer GeneQuant pro (Biochrom, 
Cambridge, England). Rnase-free water was applied as reference and 7 μl of DNA sample 
were inserted in the ultra-microvolume cuvette in order to perform the sample 
concentration and purity quantification, by reading adequate optical densities (230 nm, 
260 nm and 280 nm). The presence of nucleotides and proteins were detected at a 
wavelength of 280 nm, while at the 260 nm wavelength only detects nucleotides. At a 
wavelength of 230 nm, the presence of contaminants was assessed.   
2.3. Genotyping 
 
Sample genotyping was performed by PCR-SSP (Polymerase Chain Reaction – 
Sequence Specific Primers) technique, based on the specific amplification of defined 
regions allele. Several polymorphic points of genes encoding: APOA1  -75 G>A, APOB 
R3500Q, APOC3 C3175G,  APOC3  T3206G,  APOE  Cys112Arg,  APOE  Arg158Cys,  CETP  
G279A, CETP  R451Q,  PON1  Q192R,  NPY  Leu7Pro,  PPARG  Pro12Ala (Table 4). Primers 
used were obtained by collaboration with Genebox (Biocant- Cantanhede, Portugal) 
"Nutri Box Kit". 
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Table 4. Lipid metabolism common polymorphisms analyzed in this study. 
 
Gene Genetic variant 
NCBI SNP 
DataBase 
Region  
of gene 
Cytogenetic 
Localization Position Alleles 
APOA1 APOA1  -75 G>A rs670 Promotor 11p23.24 -75 G>A 
APOB APOB R3500Q rs5742904 Exon 26 2p24.1 3500 G>A 
APOC3 
APOC3 C3175G 
APOC3  T3206G 
rs5128 
rs4225 
Exon 4 
3’UTR 
11q23 
3175 
3206 
C>G 
T>G 
APOE 
APOE  Cys112Arg 
APOE  Arg158Cys 
rs429358 
rs7412 
Exon 4 16q13.2 
112 
158 
C>T 
CETP 
CETP  G279A (TaqIB) 
CETP R451Q (G1533A) 
rs708272 
rs1800777 
Intron 1 
Exon 15 
19q13.32 
279 
1533 
G>A 
G>A 
NPY NPY  Leu7Pro (T1128C) rs16139 
Coding 
region 
7q15.1 1128 T>C 
PON1 PON1  Q192R rs662 
coding 
region 
7p21.3 192 A>G 
PPARG PPARG  Pro12Ala rs1801282 Exon 2 3p25.2 12 C>G 
 
2.3.1. Amplification by Polymerase Chain Reaction-Sequence Specific 
Primers (PCR-SSP) 
 
Polymorphisms genotyping was carried through commercial kits “Nutri Box Kit” 
(Genebox, Cantanhede - Portugal) using PCR-SSP (Polymerase Chain Reaction – Sequence 
Specific Primers) technique. These kits included internal, negative and positive controls 
for each sample. In this process it was used for typing plates 96 wells, and was placed into 
each well 5 µL of the pair of specific primers, 2 µL of DNA sample and 3 µL of reaction 
mixture. The plates were sealed and placed in a MyCycler Thermal Cycler of 96 wells 
(Biorad, California, USA). The detection of mutations was performed using the displayed 
program present in Table 5. The amplified PCR products was analysed by electrophoresis 
with a SYBR Safe (Molecular Probes, Oregon – USA) in 2% agarose gel and visualized in a 
ultra-violet (UV) transilluminator (UVi Tech, Cambridge, United Kingdom). 
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Table 5. Protocol of the program to amplification by PCR-SSP (Polymerase Chain Reaction – 
Sequence Specific Primers), from Genebox, Cantanhede – Portugal. 
 
Step Temperature Time Number of cycles 
Initial denature 95º C 1 Min 1 
Denature 
Annealing 
Extension 
95º C 
70º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
 
5 
Denature 
Annealing 
Extension 
95º C 
65º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
 
21 
Denature 
Annealing 
Extension 
95º C 
55º C 
72º C 
25 Sec 
1 Min 
2 Min 
 
4 
Final extension 72º C 10 Min 1 
 
2.3.2. Electrophoresis in agarose gel 
PCR reactions, after amplification, were submitted to electrophoresis by 2% 
agarose gel in order to identify the amplified products. Agarose Routine Grade (NZYTech, 
Lisbon, Portugal) was dissolved in 1x TAE (Tris-acetate-EDTA) (NZYTech, Lisbon, Portugal) 
and distillated water and agitated for 15 seconds. Then the solution was transferred to 
the microwaves to complete dissolution of agarose (approximately 2 min at 900w). 
Afterwards, the solution was cool down and 1x10-5 SYBR Safe (Molecular Probes, Oregon 
– USA) a dye that allows the visualization of DNA under the UV light incidence, were 
added and the solution was agitated for 15 seconds for homogenization. Solution was 
after putted into a cradle until it solidifies under the environment temperature. After 
solidification, the solidified gel was inserted in the plastic gel box, previously filled with 1x 
TAE (NZYTech, Lisbon, Portugal). PCR samples were inserted into the gel wells and they 
were left running for 10 minutes under the 300 volts of the Power Pac Basic device (Bio-
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Rad, California, USA). Finally, PCR products were visualized under UV light by a 
transilluminator (UVi Tech, Cambridge, United Kingdom). Results were further registered 
by a digital camera (NIKON DMX1200F).    
  2.4. Statistical analysis 
2.4.1. Analysis of purity and concentration of DNA 
DNA samples purity and concentration study consisted on the calculation of the 
means, standard-deviations and confidence levels relatively to their concentrations and 
contamination quantity. This statistical analysis aimed to verify if the conditions of the 
DNAs were acceptable for the validation of the results in the study. 
2.4.2. Allele and genotype frequencies of polymorphisms 
Allele and genotype frequencies were calculated from obtained percentages for 
each studied polymorphism. In order to assess if the mutations were in equilibrium, chi-
square test was performed using the Hardy-Weinberg equilibrium as reference. APOA1  -75 
G>A, APOB R3500Q, APOC3 C3175G, APOC3 T3206G, APOE Cys112Arg, APOE Arg158Cys,  
CETP G279A, CETP R451Q, NPY Leu7Pro, PON1 Q192R and PPARG Pro12Ala frequencies 
were compared between different groups (SCA versus control and tumour localization) 
using STATISTICA 14 (StatSoft, Inc., 2013) based on chi-square (2) test and Exact Fisher 
test. The significance level was set at p<0.05, odds ratio (OR) and 95% confidence intervals 
(CI) for relative risks (RR) were also calculated for each variation. 
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Chapter III 
Results 
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3. Results 
3.1. Clinical pathology data 
 
The individual distributions of SCA subjects included in the study, according to 
their clinical pathological features of biological samples are presented in the Table 3. The 
distribution of SCA subjects by gender shows a predominance of the disease in male 
subjects comparing with female individuals (75% versus 25%). In terms of tumour 
localization, it was observed a small difference of gender distribution among colon and 
rectum groups, however, not significant differences were found (Table 6). Moreover, 46% 
(31/68) of the SCA biopsies were located in colon and 54% (37/100) of the SCA biopsies 
were located in rectum (Table 6). Also, there were not significant differences between 
mean age in both groups (colon samples:  mean age of 73.7 +/- 10 years; rectum samples: 
mean age of 71.2 +/-12.1 years). 
 
Table 6. Gender distribution among colon and rectum groups. 
 
 Colon Rectum 
p-value 
95% IC 
Gender n % n % OR RR 
Male 25 81 26 70 
0.364 
0.567 (0.182-1.767) 0.788 (0.506-1.226) 
Female 6 19 11 30 1.763 (0.566-5.491) 1.269 (0.816-1.975) 
Total 31 100 37 100    
 
3.2. Analysis of DNA purity and concentration  
 
Although DNA concentration were not uniform (+/-29.3g/ml) and lower than the 
standard value (100 g/ml)132 (Table 7), the amplification by PCR-SSP occurred without 
problems, since the amplification protocol was adapted to the DNA concentration of 
samples. Although the mean values of purity of DNAs range between acceptable limits, 
1.6-1.8 to O.D.260nm/O.D.280nm132 and 0.4-0.6 to O.D.230nm/O.D.260nm132, some 
DNAs show high quantities of contaminants and proteins with a confidence interval being 
above certain acceptable limits (Table 7).  
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Furthermore, coefficients of variation show the existence of samples that deviate 
from acceptable patterns, whether in DNA concentration and in contaminants quantity. 
These DNA can affect some results, however the majority of samples show a level of purity 
highly acceptable (Table 7). Globally, PCR-SSP did not present major amplification 
problems. 
 
Table 7. Means and standard-deviations of DNA samples purity and concentration values 
 
 Concentration O.D.260nm/O.D.280nm O.D.230nm/O.D.260nm 
Mean 42.4 1.83 0.54 
Standard Deviation 29.316 0.09 0.15 
Variation Coefficient 69.14% 5% 28% 
Confidence Interval (95%)  1.7-1.9 0.4-0.7 
 
3.3. Analyze of allele and genotype frequencies from polymorphisms 
in SCA and controls 
 
Allele and genotype frequencies from polymorphisms of APOA1, APOB, APOC3, 
APOE, CETP, NPY, PON1 and PPARG genes in SCA subjects and controls are exhibited in 
Tables 8-13. Almost all genes presented statistically significant differences between both 
groups to allele frequencies, except the APOE gene and APOC3 T3206G variant had not 
statistically significant differences among groups (Table 8). According to genotype 
frequencies, most genes exhibited statistically significant difference between different 
groups, excluding APOA1 -75GG, APOA1 -75GA, APOC3 3206TT, APOE E2/E2, APOE E2/E3, 
APOE E2/E4, APOE E3/E3, CETP 451CG, PON1 192GG, PPARG 12CC and PPARG 12CG that 
had no statistically significant differences among groups (Table 9, 11 and 13). Finally, 
most of the polymorphisms analyzed were in Hardy Weinberg equilibrium (p>0.05), 
except the APOC3 T3206G (p=0.02) and PON1 Q192R (p=0.05) (Table 20).  
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3.3.1. APOA1 -75 G>A, APOB R3500Q, APOC3 C3175G, APOC3 T3206G 
and APOE Cys112/158Arg distribution among SCA and controls 
 
Allele frequencies of APOA1 -75G (wild-type - wt) polymorphism were significantly 
higher in controls than SCA subjects (52% versus 69%; p=0.002; OR= 0.49; 95% CI 0.31-
0.77) (Table 8 and Figure 18.A). In contrast, allele frequencies of APOA1 -75A (mutant) 
polymorphism was more prevalent in SCA subjects (48% versus 31%; p=0.002; OR=2.04; 
95% CI 1.30-3.20). Related to genotype frequencies, APOA1 -75AA (mutant genotype) was 
significantly higher in SCA subjects than among controls (32% versus 12%; p=0.001; 
OR=3.51; 95% CI 1.59-7.72) (Table 9 and Figure 18.B).  
Allele frequencies of APOB 3500G (wt) polymorphism were significantly higher in 
controls than in SCA subjects (79% versus 99%; p<0.0001; OR=0.04; 95% CI 0.01-0.17), 
while APOB 3500A (mutant) polymorphism was more prevalent in SCA subjects (21% 
versus 1%; p<0.0001; OR=25.67; 95% CI 6.00-109.82) (Table 8 and Figure 18.C). APOB 
3500GG genotype (wt) was significantly higher in controls than among SCA subjects (66% 
versus 99%; p<0.0001; OR=0.02; 95% CI 0.003-0.15) (Table 9 and Figure 18.D). 
Contrasting, APOB 3500GA heterozygotic genotype was more frequent in SCA subjects 
(27% versus 1%; p<0.0001; OR=35.64; 95% CI 4.62-274.70). Furthermore, the genotype 
APOB1 3500AA was presented only in SCA subjects (7% versus 0%; p=0.01).  
Allele frequencies of APOC3 3175C (wt) polymorphism were significantly higher in 
controls than in SCA subjects (54% versus 93%; p<0.0001; OR=0.09; 95% CI 0.05-0.17), 
however allele frequencies of APOC3 3175G (mutant) polymorphism was more frequent 
in SCA subjects (46% versus 7%; p<0.0001; OR=11.13; 95% CI 5.87-21.10) (Table 8 and 
Figure 18.E). APOC3 3175CC wt genotype was significantly higher in controls than in SCA 
subjects (28% versus 83%; p<0.0001; OR=0.08; 95% CI 0.04-0.17), whereas APOC3 3175CG 
(53% versus 15%; p<0.0001; OR=6.38; 95% CI 3.08-13.18) and APOC3 3175CC (19% versus 
2%; p=0.0002; OR=11.58; 95% CI 2.52-53.22) mutant genotypes were more prevalent 
among SCA subjects (Table 9 and Figure 18.F). 
Finally, APOC3 3206TG genotype was significantly higher in controls than in SCA 
subjects (19% versus 37%; p=0.02; OR=0.40; 95% CI 0.19-0.83), while genotype APOC3 
3206GG was present only SCA subjects (19% versus 0%; p=0.0001) (Table 9 and Figure 
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18.G), and APOE E4/E4 genotype showed significant differences, being present only in 
controls subjects (0% versus 8%; p=0.02) (Table 9 and Figure 18.H). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Allele and genotype frequencies of apolipoproteins genes polymorphisms among the 
SCA and controls subjects: (A) Allele frequencies and (B) Genotype frequencies of APOA1 -75 G>A; 
(C) Allele frequencies and (D) Genotype frequencies of APOB R3500Q; (E) Allele frequencies and 
(F) Genotype frequencies of APOC3 C3175G; Genotype frequencies of (G) APOC3 T3206G and (H) 
APOE Cys112/158Arg (* p≤0.05; **p≤0.001; ***p≤0.0001). 
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Table 8. Allele frequencies distribution of APOA1 -75 G>A, APOB R3500Q, APOC3 C3175G, APOC3 
T3206G and APOE Cys112/158Arg among SCA and control subjects. 
 
 
*Statistically significant; n.s: not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G<A        
G 71 52 138 69 
0.002* 
0.49 (0.31-0.77) 0.66(0.51-0.86) 
A 65 48 62 31 2.04 (1.30-3.20) 1.51 (1.17-1.94) 
Total 136 100 200 100    
APOB R3500Q        
G 108 79 198 99 
<0.0001* 
0.04 (0.01-0.17) 0.38 (0.32-0.45) 
A 28 21 2 1 25.67 (6.00-109.82) 2.64 (2.21-3.16) 
Total 136 100 200 100    
APOC3 C3175G        
C 74 54 186 93 
<0.0001* 
0.09 (0.05-0.17) 0.35 (0.28-0.43) 
G 62 46 14 7 11.13 (5.87-21.10) 2.87 (2.30-3.57) 
Total 136 100 200 100    
APOC3 T3206G        
T 97 71 126 63 
n.s 
1.46 (0.91-2.34) 1.26 (0.94-1.69) 
G 39 29 74 37 0.68 (0.43-1.09) 0.79 (0.59-1.07) 
Total 136 100 200 100    
APOE Cys112/158Arg        
E2 13 10 13 6 
n.s 
1.52 (0.68-3.39) 1.26 (0.84-1.90) 
E3 106 78 156 78 1.0 (0.59-1.69) 1.0 (0.73-1.36) 
E4 17 12 31 16 0.78 (0.41-1.47) 0.86 (0.57-1.29) 
Total 136 100 200 100    
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Table 9. Genotype frequencies distribution of APOA1 -75 G>A, APOB R3500Q, APOC3 C3175G, 
APOC3 T3206G and APOE Cys112/158Arg among SCA and control subjects. 
 
Genotype Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G>A        
GG 25 37 50 50 
n.s 
0.58 (0.31-1.09) 0.72 (0.49-1.06) 
GA 21 31 38 38 0.73 (0.38-1.40) 0.83 (0.55-1.24) 
AA 22 32 12 12 0.001* 3.51 (1.59-7.72) 1.88 (1.34-2.65) 
Total 68 100 100 100    
APOB R3500Q        
GG 45 66 99 99 
<0.0001* 
0.02 (0.003-0.15) 0.33 (0.25-0.42) 
GA 18 27 1 1 35.64 (4.62-274.70) 2.82 (2.20-3.62) 
AA 5 7 0 0 0.01* Infinity (NaN-Infinity) 2.59 (2.13-3.14) 
Total 68 100 100 100    
APOC3 C3175G        
CC 19 28 83 83 
<0.0001* 
0.08 (0.04-0.17) 0.25 (0.16-0.39) 
CG 36 53 15 15 6.38 (3.08-13.18) 2.58 (1.83-3.64) 
GG 13 19 2 2 0.0002* 11.58 (2.52-53.22) 2.41 (1.80-3.22) 
Total 68 100 100 100    
APOC3 T3206G        
TT 42 52 63 63 n.s 0.95 (0.50-1.79) 0.97 (0.67-1.41) 
TG 13 19 37 37 0.02 0.40(0.19-0.83) 0.56 (0.34-0.93) 
GG 13 19 0 0 <0.0001* Infinity (NaN-Infinity) 2.82 (2.28-3.48) 
Total 68 100 100 100    
APOE Cys112/158Arg        
E2/E2 3 5 1 1 
n.s 
4.57 (0.47-44.88) 1.89 (1.04-3.44) 
E2/E3 5 7 10 10 0.71 (0.23-2.19) 0.81 (0.39-1.70) 
E2/E4 2 3 1 1 3.0 (0.27-33.76) 1.67 (0.73-3.79) 
E3/E3 43 63 66 66 0.89 (0.47-1.69) 0.93 (0.64-1.36) 
E3/E4 15 22 14 14 1.74 (0.78-3.89) 1.36 (0.90-2.05) 
E4/E4 0 0 8 8 0.02* 0 (0-NaN) 0 (0-NaN) 
Total 68 100 100 100    
*Statistically significant; n.s: not significant 
 
3.3.2. CETP G279A and CETP R451Q (G>A) polymorphisms 
distribution among SCA and controls 
 
Allele frequencies CETP 279G (wt) polymorphism were significantly higher in 
controls than in SCA subjects (50% versus 71%; p<0.0001; OR=0.41; 95% CI 0.26-0.64), 
contrarily allele frequencies of CETP 279A mutant polymorphism were more prevalent in 
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SCA subjects (50% versus 29%; p<0.0001; OR=2.45; 95% CI 1.55-3.86) (Table 10 and Figure 
19.A). CETP 279GG wt genotype was significantly higher in controls than among SCA 
subjects (12% versus 71%; p<0.0001; OR=0.05; 95% CI 0.02-0.13), whereas CETP 279GA 
(76% versus 28%; p<0.0001; OR=8.36; 95% CI 4.108-17.00) and CETP  279AA (12% versus 
1%; p=0.003; OR=13.20; 95% CI 1.61-108.17) genotypes were more frequent between 
SCA subjects (Table 11 and Figure 19.B).  
Allele frequencies of CETP 451G (wt) polymorphism were significantly higher in 
controls than in SCA subjects (74% versus 98%; p<0.0001; OR=0.07; 95% CI 0.03-0.19), in 
contrast allele frequencies of CETP 451A (mutant) variant was more frequent in SCA 
subjects (26% versus 2%; p<0.0001; OR=14.04; 95% CI 14.5.34-36.89) (Table 10 and Figure 
19.C). CETP 451GG genotype was significantly higher in controls than among SCA subjects 
(63% versus 90%; p<0.0001; OR=0.19; 95% CI 0.08-0.43), while CETP 451AA mutant 
genotype was more frequent between SCA subjects (16% versus 0%; p<0.0001) (Table 11 
and Figure 19.D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Allele and genotype frequencies of CETP gene polymorphisms among SCA and controls 
subjects: (A) Allele frequencies and (B) Genotype frequencies of CETP G279A; (C) Allele 
frequencies and (D) Genotype frequencies of CETP R451Q (G>A) (**p≤0.001; ***p≤0.0001). 
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Table 10. Allele frequencies distribution of CETP G279A and CETP R451Q (G>A) among SCA and 
control subjects. 
*Statistically significant 
 
 
Table 11. Genotype frequencies distribution of CETP G279A and CETP R451Q (G>A) among SCA 
and control subjects. 
 
 *Statistically significant; n.s: not significant 
 
 
 
 
 
 
 
 
 
 
 
Allele Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
CETP G279A        
G 68 50 142 71 
0.0001* 
0.41 (0.26-0.64) 0.60 (0.47-0.77) 
A 68 50 58 29 2.45 (1.55-3.86) 1.67 (1.29-2.15) 
Total 136 100 200 100    
CETP R451Q        
G 100 74 195 98 
<0.0001* 
0.07 (0.03-0.19) 0.39 (0.32-0.47) 
A 36 26 5 2 14.04 (5.34-36.89) 2.59 (2.13-3.15) 
Total 136 100 200 100    
Genotype 
Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
CETP G279A        
GG 8 12 71 71 
<0.0001* 
0.05 (0.02-0.13) 0.15 (0.08-0.29) 
GA 52 76 28 28 8.36 (4.11-17.00) 3.58 (2.23-5.73) 
AA 8 12 1 1 0.003* 13.20 (1.61-108.17) 2.36 (1.74-3.20) 
Total 68 100 100 100    
CETP R451Q        
GG 43 63 90 90 <0.0001* 0.19 (0.08-0.43) 0.45 (0.33-0.63) 
GA 14 21 10 10 n.s 2.33 (0.97-5.62) 1.56 (1.04-2.32) 
AA 11 16 0 0 <0.0001* Infinity (NaN-Infinity) 2.75 (2.24-3.39) 
Total 68 100 100 100    
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3.3.3. NPY Leu7Pro, PON1 Q192R (A>G) and PPARG Pro12Ala 
polymorphisms distribution among SCA and controls 
 
Allele frequencies of NPY 7T (wt) polymorphism were higher in controls than in 
SCA subjects (73% versus 98%; p<0.0001; OR=0.05; 95% CI 0.02-0.16), while allele 
frequencies NPY 7C (mutant) polymorphism was more frequent between SCA subjects 
(27% versus 2%, p<0.0001; OR=18.31; 95% CI 6.35-52.83) (Table 12 and Figure 20.A). NPY 
7TT wt genotype was significantly higher in controls than among SCA subjects (60% versus 
96%; p<0.0001; OR=0.06; 95% CI 0.02-0.19), however NPY 7TC (25% versus 4%; p<0.0001; 
OR=8; 95% CI 2.56-25.04) and NPY 7CC (15% versus 0%; p<0.0001) genotypes were more 
frequent in SCA subjects (Table 13 and Figure 20.B). 
Allele frequencies PON1 192A (wt) polymorphism was higher in controls than 
among SCA subjects (62% versus 83%; p<0.0001; OR=0.33; 95% CI 0.20-0.55). On the 
other hand, allele frequencies PON1 192G (mutant) was more prevalent between SCA 
subjects (38% versus 17%, p<0.0001; OR=3.02; 95% CI 1.82-5.01) (Table 12 and Figure 
20.C). PON1 192AA genotype was significantly higher in controls than in SCA subjects 
(34% versus 72%; p<0.0001; OR=1.00; 95% CI 0.10-0.39), while PON1 192AG genotype 
was more frequent between SCA subjects (56% versus 22%; p<0.0001; OR=4.49; 95% CI 
2.29-8.80) (Table 13 and Figure 20.D). 
Finally, allele frequencies of PPARG 12C (wt) polymorphism are higher in controls 
than in SCA subjects (85% versus 93%; p<0.0001; OR=0.41; 95% CI 0.20-0.84), while allele 
frequencies of PPARG 12G (mutant) polymorphism was more prevalent between SCA 
subjects (15% versus 7%, p<0.016; OR=2.426; 95% CI 1.187-4.960) (Table 12 and Figure 
20.E). PPARG 12GG genotype was more frequent among SCA subjects (10% versus 0%; 
p=0.001) (Table 13 and Figure 20.F). 
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Figure 20. Allele and genotype frequencies distribution among SCA and controls subjects: (A) 
Allele and (B) Genotype frequencies of NPY Leu7Pro polymorphism; (C) Allele and (D) Genotype 
frequencies of PON1 Q192R (A>G) polymorphism; (E) Allele and (F) Genotype frequencies of 
PPARG Pro12Ala polymorphism (*p≤0.05; **p≤0.001; ***p≤0.0001). 
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Table 12. Allele frequencies distribution of NPY Leu7Pro, PON1 Q192R (A>G) and PPARG Pro12Ala 
among SCA and control subjects. 
 
 
 
*Statistically significant 
 
 
Table 13. Genotype frequencies distribution of NPY Leu7Pro, PON1 Q192R (A>G) and PPARG 
Pro12Ala among SCA and control subjects. 
*Statistically significant; n.s: not significant 
 
Allele 
Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
NPY Leu7Pro        
T 99 73 196 98 
<0.0001* 
0.05 (0.02-0.16) 0.37 (0.31-0.45) 
C 37 27 4 2 18.31 (6.35-52.83) 2.69 (2.22-3.25) 
Total 136 100 200 100    
PON1 Q192R        
A 84 62 166 83 
<0.0001* 
0.33 (0.20-0.55) 0.56 (0.44-0.71) 
G 52 38 34 17 3.02 (1.82-5.01) 1.80 (1.41-2.30) 
Total 136 100 200 100    
PPARG Pro12Ala        
C 115 85 186 93 
0.02* 
0.41 (0.20-0.84) 0.64 (0.47-0.87) 
G 21 15 14 7 2.43 (1.19-4.96) 1.57 (1.16-2.13) 
Total 136 100 200 100    
Genotype 
Frequencies 
SCA and Controls 
SCA Controls 
p-value 
95 % CI 
n % n % OR RR 
NPY Leu7Pro        
TT 41 60 96 96 
<0.0001* 
0.06 (0.02-0.19) 0.34 (0.26-0.46) 
TC 17 25 4 4 8.00 (2.56-25.04) 2.33 (1.72-3.16) 
CC 10 15 0 0 Infinity (NaN-Infinity) 0.37 (0.30-0.45) 
Total 68 100 100 100    
PON1 Q192R        
AA 23 34 72 72 
<0.0001* 
0.20 (0.10-0.39) 0.39 (0.26-0.59) 
AG 38 56 22 22 4.49 (2.29-8.80) 2.28 (1.59-3.27) 
GG 7 10 6 6 n.s 1.80 (0.58-5.60) 1.37 (0.80-2.35) 
Total 68 100 100 100    
PPARG Pro12Ala        
CC 54 80 86 86 
n.s 
0.63 (0.28-1.42) 0.77 (0.50-1.18) 
CG 7 10 14 14 0.70 (0.27-1.85) 0.80 (0.43-1.56) 
GG 7 10 0 0 0.001* Infinity (NaN-Infinity) 2.64 (2.17-3.22) 
Total 68 100 100 100    
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3.4. Lipid metabolism genes polymorphisms in SCA stratified by 
clinical pathological features 
3.4.1. Gender 
 
Polymorphisms distribution of lipid metabolism in SCA subjects between males 
and female (genders) did not show statistically significant differences among them (Table 
14 and 15). 
Table 14. Allele frequencies distribution between genders. 
 
Allele Frequencies 
Gender 
Male Female 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G>A        
G 56 55 15 44 
n.s 
0.65 (0.30-1.42) 0.72 (0.40-1.30) 
A 46 45 19 56 1.54 (0.71-3.37) 1.38 (0.77-2.49) 
Total 102 100 34 100    
APOB R3500Q        
G 79 77 29 85 
n.s 
1.69 (0.59-4.86) 1.50 (0.64-3.53) 
A 23 23 5 15 0.59 (0.21-1.70) 0.67 (0.28-1.56) 
Total 102 100 34 100    
APOC3 C3175G        
C 53 52 21 62 
n.s 
1.49 (0.68-3.30) 1.35 (0.74-2.48) 
G 49 48 13 38 0.67 (0.30-1.48) 0.74 (0.40-1.35) 
Total 102 100 34 100    
APOC3 T3206G        
T 75 74 22 65 
n.s 
0.66 (0.29-1.51) 0.74 (0.41-1.34) 
G 27 26 12 35 1.52 (0.66-3.47) 1.36 (0.75-2.47) 
Total 102 100 34 100    
APOE Cys112/158Arg        
E2 10 10 3 9 
n.s 
0.89 (0.23-3.44) 0.92 (0.32-2.59) 
E3 80 78 26 76 0.89 (0.36-2.25) 0.92(0.47-1.82) 
E4 12 12 5 15 1.29 (0.42-3.98) 1.22 (0.54-2.69) 
Total 102 100 34 100    
CETP G279A        
G 54 63 14 41 
n.s 
0.62 (0.28-1.37) 0.70 (0.39-1.27) 
A 48 47 20 59 1.61 (0.73-3.53) 1.43 (0.79-2.59) 
Total 102 100 34 100    
n.s: not significant 
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Table 14. Allele frequencies distribution between genders (cont). 
 
CETP R451Q        
G 73 72 27 79 
n.s 
1.53 (0.60-3.91) 1.39 (0.66-2.91) 
A 29 28 7 21 0.65 (0.26-1.66) 0.72 (0.26-1.66) 
Total 102 100 34 100    
NPY Leu7Pro        
T 71 70 28 82 
n.s 
2.04 (0.77-5.42) 1.74 (0.79-3.87) 
C 31 30 6 18 0.49 (0.18-1.30) 0.57 (0.26-2.02) 
Total 102 100 34 100    
PON1 Q192R        
A 61 60 23 68 
n.s 
1.41 (0.62-3.19) 1.29 (0.69-2.43) 
G 41 40 11 32 0.71 (0.31-1.62) 0.77 (0.41-1.45) 
Total 102 100 34 100    
PPARG Pro12Ala        
C 88 86 27 79 
n.s 
0.61 (0.22-1.68) 0.70 (0.35-1.40) 
G 14 14 7 21 1.63 (0.60-4.45) 1.42 (0.71-2.83) 
Total 102 100 34 100    
 n.s: not significant 
 
 
Table 15. Genotype frequencies distribution between genders. 
 
Genotype Frequencies 
Gender 
Male Female 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G>A        
GG 20 39 5 29 
n.s 
0.65 (0.20-2.11) 0.72 (0.29-1.80) 
GA 16 31 5 29 0.91 (0.27-3.02) 0.93 (0.38-2.31) 
AA 15 30 7 42 1.68 (0.54-5.2) 1.46 (0.64-3.33) 
Total 51 100 17 100    
APOB R3500Q        
GG 32 63 13 76 
n.s 
1.93 (0.55-6.78) 1.66 (0.61-4.52) 
GA 15 29 3 18 0.51 (0.13-2.05) 0.60 (0.19-1.83) 
AA 4 8 1 6 0.73 (0.08-7.06) 0.79 (0.13-4.78) 
Total 51 100 17 100    
APOC3 C3175G        
CC 13 25 6 35 
n.s 
1.59 (0.49-5.18) 1.41 (0.61-3.26) 
CG 27 53 9 53 1.00 (0.33-3.00) 1.00 (0.44-2.28) 
GG 11 22 2 12 0.48 (0.10-2.45) 0.56 (0.15-2.17) 
Total 51 100 17 100    
n.s: not significant 
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Table 15. Genotype frequencies distribution between genders (cont). 
 
APOC3 T3206G        
TT 32 63 10 59 
n.s 
0.85 (0.28-2.60) 0.88 (0.38-2.03) 
TG 11 21 2 12 0.48 (0.10-2.45) 0.56 (0.15-2.17) 
GG 8 16 5 29 2.24 (0.62-8.12) 1.76 (0.75-4.13) 
Total (68) 51 100 17 100    
APOE Cys112/158Arg        
E2/E2 2 4 1 6 
n.s 
1.53 (0.13-18.03) 1.35 (0.26-7.09) 
E2/E3 5 10 0 0 0 (0-NaN) 0 (0-NaN) 
E2/E4 1 2 1 6 3.13 (0.18-52.87) 2.06 (0.48-8.79) 
E3/E3 32 63 11 65 1.09 (0.35-3.42) 1.07 (0.45-2.53) 
E3/E4 11 21 4 23 1.12 (0.30-4.12) 1.09 (0.415-2.848) 
E4/E4 0 0 0 0 0 0 
Total 51 100 17 100    
CE<TP G279A        
GG 7 14 1 6 
n.s 
0.39 (0.04-3.45) 0.47 (0.07-3.07) 
GA 40 78 12 71 0.66 (0.19-2.28) 0.74 (0.31-1.78) 
AA 4 8 4 23 3.62 (0.79-16.46) 2.31 (0.99-5.36) 
Total 51 100 17 100    
CETP R451Q        
GG 31 61 12 70 
n.s 
1.55 (0.47-5.06) 1.40 (0.56-3.50) 
GA 11 21 3 18 0.78 (0.19-3.21) 0.83 (0.28-2.48) 
AA 9 18 2 12 0.62 (0.12-3.21) 0.69 (0.18-2.60) 
Total 51 100 17 100    
NPY Leu7Pro        
TT 29 57 12 70 
n.s 
1.82 (0.56-5.93) 1.58 (0.63-3.98) 
TC 13 25 4 24 0.90 (0.25-3.25) 0.92 (0.35-2.45) 
CC 9 18 1 6 0.29 (0.03-4.49) 0.36 (0.05-2.44) 
Total 51 100 17 100    
PON1 Q192R        
AA 16 31 7 41 n.s 1.53 (0.49-4.75) 1.37 (0.60-3.13) 
AG 29 57 9 53  0.85 (0.28-2.57) 0.89 (0.39-2.02) 
GG 6 12 1 6  0.47 (0.05-4.20) 0.55 (0.09-3.51) 
Total 51 100 17 100    
PPARG Pro12Ala        
CC 41 80 13 76 
n.s 
0.79 (0.21-2.96) 0.84 (0.32-2.19) 
CG 6 12 1 6 0.47 (0.05-4.20) 0.54 (0.08-3.51) 
GG 4 8 3 18 2.52 (0.50-12.62) 1.87 (0.71-4.93) 
Total 51 100 17 100    
n.s: not significant 
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3.4.2. Tumour localization 
 
Allele frequencies from APOA1, APOB, APOC3, APOE, CETP, NPY, PON1 and PPARG 
common polymorphisms in colon SCA samples and rectum SCA samples are presented in 
Table 16. The majority those genes did not present a significant difference between 
groups, only PPARG had registered significant difference (Table 16). 
 
Table 16. Allele frequencies distribution in colon versus rectum SCA. 
 
Allele Frequencies 
Tumour Localization 
Colon Rectum 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G>A        
G 31 50 40 54 
n.s 
1.18 (0.60-2.31) 1.08 (0.79-1.47) 
A 31 50 34 46 0.85 (0.43-1.67) 0.93 (0.68-1.27) 
Total 62 100 74 100    
APOB R3500Q        
G 52 84 56 76 
n.s 
0.60 (0.25-1.41) 0.81 (0.58-1.23) 
A 10 16 18 24 1.67 (0.71-3.95) 1.24 (0.89-1.73) 
Total 62 100 74 100    
APOC3 C3175G        
C 34 55 40 54 
n.s 
0.97 (0.49-1.91) 0.99 (0.72-1.34) 
G 28 45 34 46 1.03 (0.52-2.03) 1.01 (0.75-1.38) 
Total 62 100 74 100    
APOC3 T3206G        
T 46 74 51 69 
n.s 
0.77 (0.36-1.64) 0.89 (0.65-1.23) 
G 16 26 23 31 1.30 (0.61-2.75) 1.12 (0.81-1.55) 
Total 62 100 74 100    
APOE Cys112/158Arg        
E2 7 11 6 8 
n.s 
0.69 (0.22-2.18) 0.83 (0.45-1.53) 
E3 48 78 58 78 1.06 (0.47-2.38) 1.03 (0.70-1.50) 
E4 7 11 10 14 1.23 (0.44-3.44) 1.09 (0.71-1.68) 
Total 62 100 74 100    
CETP G279A        
G 35 56 33 45 
n.s 
0.62 (0.315-1.225) 0.80 (0.59-1.10) 
A 27 44 41 55 1.61 (0.82-3.18) 1.24 (0.91-1.70) 
Total 62 100 74 100    
CETP R451Q        
G 45 73 55 74 
n.s 
1.09 (0.51-2.35) 1.04 (0.73-1.49) 
A 17 27 19 26 0.91 (0.43-1.96) 0.96 (0.67-1.37) 
Total 62 100 74 100    
*Statistically significant; n.s: not significant 
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Table 16. Allele frequencies distribution in colon versus rectum SCA (cont). 
 
NPY Leu7Pro        
T 45 73 54 73 
n.s 
1.02 (0.48-2.18) 1.01 (0.71-1.43) 
C 17 27 20 27 0.98 (0.46-2.09) 0.99 (0.70-1.40) 
Total 62 100 74 100    
PON1 Q192R        
A 40 65 44 59 n.s 0.81 (0.40-1.62) 0.91 (0.67-1.24) 
G 22 35 30 41  1.24 (0.62-2.49) 1.10 (0.81-1.50) 
Total 62 100 74 100    
PPARG Pro12Ala        
C 57 92 58 78 
0.04* 
0.32 (0.11-0.93) 0.66 (0.49-0.89) 
G 5 8 16 22 3.14 (1.08-9.16) 1.51 (1.12-2.04) 
Total 62 100 74 100    
*Statistically significant; n.s: not significant 
 
Allele frequencies PPARG 12C (wt) polymorphism was higher in colon SCA than in 
rectum SCA subjects (92% versus 78%; p=0.04; OR=0.32; 95% CI 0.11-0.93), while allele 
frequencies of PPARG 12G (mutant) polymorphism were more prevalent in rectum SCA 
subjects (8% versus 22%, p=0.04; OR=3.145; 95% CI 1.080-9.156) (Table 16 and Figure 
21.A) 
Allele frequencies from PPARG gene polymorphism in colon SCA versus controls 
subjects, and rectum SCA versus controls subjects were present in Table 17 and Table 18, 
respectively. Thus, allele frequencies PPARG polymorphism showed statistically significant 
differences between both rectum SCA and controls subjects groups and no difference 
between colon SCA and controls subjects. Allele frequencies PPARG 12C polymorphism 
were higher in controls than in rectum SCA samples (78% versus 93%; p=0.001; OR=0.273; 
95% CI 0.126-0.593) (Table 18 and Figure 21.B). On other hand, PPARG 12G allele 
frequencies were more prevalent in rectum SCA subjects (22% versus 7%; p=0.001; 
OR=3.665; 95% CI 1.688-7.959). 
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Figure 21. Allele frequencies of PPARG Pro12ala in (A) Colon SCA and Rectum SCA (B) Rectum SCA 
and control subjects (*p≤0.05; **p≤0.001).  
 
 
Table 17. Allele frequencies of PPARG Pro12Ala distribution among colon SCA and controls 
subjects. 
n.s: not significant 
 
 
  
Table 18. Allele frequencies of PPARG Pro12Ala distribution among rectum SCA and controls 
subjects. 
 
Allele Frequencies 
Rectum SCA and Controls 
Rectum SCA Controls p-value 95 % IC 
n % n %  OR RR 
PPARG Pro12Ala        
C 58 78 186 93 
0,001* 
3.67 (1.69-7.96) 1.63 (1.11-2.41) 
G 16 22 14 7 0.27 (0.13-0.59) 0.61 (0.41-0.90) 
Total 74 100 200 100    
*Statistically significant 
 
 
 
 
 
 
Allele 
Frequencies 
Colon SCA and Controls 
Colon SCA Controls p-value 95 % IC 
n % n %  OR RR 
PPARG Pro12Ala        
C 57 92 186 93 
n.s 
1.17 (0.40-3.38) 1.04 (0.79-1.37) 
G 5 8 14 7 0.86 (0.30-2.49) 0.96 (0.73-1.27) 
Total 62 100 200 100    
* 
** 
** 
A B 
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Genotype frequencies from APOA1, APOB, APOC3, APOE, CETP, NPY, PON1 and 
PPARG common polymorphisms in colon SCA and rectum SCA samples are presented in 
Table 19. The majority of those genes did not presented a significant difference between 
groups, except APOB 3500GA, APOC3 3206TG, CETP 279AA genotypes had reported 
significant difference among groups (Table 19). 
APOB 3500GA genotype was significantly higher in rectum SCA than in colon SCA 
samples (13% versus 38%; p<0.03; OR=4.11; 95% CI 1.19-14.235) (Table 19 and Figure 
22.A). Also, APOC3 3206TG genotype was significantly higher in colon SCA than rectum 
SCA samples (32% versus 8%; p<0.02; OR=0.185; 95% CI 0.05-0.75) (Table 19 and Figure 
22.B). In contrast, CETP 279AA genotype was only present in rectum SCA samples (0% 
versus 22%; p<0.006) (Table 19 and Figure 22.C).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Genotype frequencies in Colon SCA and Rectum SCA to (A) APOB R3500Q, (B) APOC3 
T3206G and (C) CETP G279A (*p≤0.05). 
 
 
 
 
 
 
 
* 
* 
* 
A B 
C 
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Table 19. Genotype frequencies distribution in colon and rectum SCA samples. 
 
Genotype Frequencies 
Tumour Localization 
Colon Rectal 
p-value 
95 % CI 
n % n % OR RR 
APOA1 -75 G>A        
GG 9 29 16 43 
n.s 
1.86 (0.68-5.12) 1.31 (0.86-2.00) 
GA 13 42 8 22 0.38 (0.13-1.10) 0.62 (0.34-1.11) 
AA 9 29 13 35 1.32 (0.47-3.70) 1.13 (0.73-1.77) 
Total 31 100 37 100    
APOB R3500Q        
GG 24 77 21 57 n.s 0.38 (0.13-1.11) 0.67 (0.44-1.01) 
GA 4 13 14 38 0.03* 4.11 (1.19-14.24) 1.69 (1.15-2.49) 
AA 3 10 2 5 n.s 0.53 (0.08-3.42) 0.72 (0.24-2.15) 
Total 31 100 37 100    
APOC3 C3175G        
CC 9 29 10 27 
n.s 
0.91 (0.31-2.62) 0.96 (0.58-1.57) 
CG 16 52 20 54 1.10 (0.42-2.87) 1.05 (0.68-1.62) 
GG 6 19 7 19 0.97 (0.29-3.27) 0.99 (0.56-1.73) 
Total 31 100 37 100    
APOC3 T3206G        
TT 18 58 24 65 n.s 1.33 (0.50-3.56) 1.14 (0.72-1.82) 
TG 10 32 3 8 0.02* 0.19 (0.05-0.75) 0.37 (0.14-1.03) 
GG 3 10 10 27 n.s 3.46 (0.86-13.94) 1.57 (1.05-2.34) 
Total 31 100 37 100    
APOE Cys112/158Arg        
E2/E2 2 6 1 3 
n.s 
0.40 (0.03-4.67) 0.60 (0.12-3.03) 
E2/E3 2 6 3 8 1.28 (0.20-8.19) 1.11 (0.52-2.36) 
E2/E4 1 3 1 3 0.83 (0.05-13.90) 0.92 (0.23-3.73) 
E3/E3 20 65 23 62 0.90 (0.34-2.44) 0.96 (0.61-1.49) 
E3/E4 6 20 9 24 1.34 (0.42-4.30) 1.14 (0.70-1.85) 
E4/E4 0 0 0 0 0 0 
Total 31 100 37 100    
CETP G279A        
GG 4 13 4 11 
n.s 
0.82 (0.19-3.58) 0.91 (0.44-1.89) 
GA 27 87 25 67 0.31 (0.09-1.08) 0.64(0.43-0.96) 
AA 0 0 8 22 0.006* Infinity (NaN-Infinity) 2.07 (1.59-2.69) 
Total 31 100 37 100    
CETP R451Q        
GG 19 61 24 65 
n.s 
1.17 (0.43-3.13) 1.07 (0.68-1.70) 
GA 7 23 7 19 0.80 (0.25-2.60) 0.90 (0.51-1.60) 
AA 5 16 6 16 1.01 (0.28-3.68) 1.00 (0.56-1.81) 
Total 31 100 37 100    
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Table 19. Genotype frequencies distribution in colon and rectum SCA samples (cont). 
 
NPY Leu7Pro        
TT 19 61 22 59 
n.s 
0.93 (0.35-2.46) 0.97 (0.62-1.50) 
TC 7 23 10 27 1.27 (0.42-3.86) 1.11 (0.69-1.79) 
CC 5 16 5 14 0.81 (0.21-3.11) 0.91 (0.47-1.76) 
Total 31 100 37 100    
PON1 Q192R        
AA 11 36 12 32 n.s 0.87 (0.32-2.39) 0.94 (0.59-1.50) 
AG 18 58 20 54  0.85 (0.32-2.23) 0.93 (0.60-1.43) 
GG 2 6 5 14  2.27 (0.41-12.59) 1.36 (0.80-2.30) 
Total 31 100 37 100    
PPARG Pro12Ala        
CC 28 90 26 70 
n.s 
0.25 (0.06-1.01) 0.61 (0.42-0.90) 
CG 1 3 6 16 5.81 (0.66-51.15) 1.69 (1.14-2.49) 
GG 2 7 5 14 2.27 (0.41-12.59) 1.36 (0.80-2.30) 
Total 31 100 37 100    
*Statistically significant; n.s: not significant 
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Chapter IV 
Discussion 
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4. Discussion 
 
CRC pathogenesis is a multistep process involving genetic and environmental 
factors that influence disease progression.19 Between these factors, dietary44,25 and 
genetic polymorphisms8 are fundamental for SCA susceptibility. Furthermore, there are 
recent evidences that several SNP associated to SCA development may be influenced by 
high fat diet, lifestyle and other social habits.133 Moreover, association studies have 
showed a relation between the presence of APOA1 -75 G>A72, APOB R3500Q84, APOC3 
C3175G89, APOC3 T3206G57, APOE Cys112/158Arg58, CETP G279A60, CETP R451Q59, NPY 
Leu7Pro134, PON1 Q192R62, PPARG Pro12Ala135 polymorphisms and the decrease of 
cholesterol and/or triglycerides plasma concentrations, as well as 
hyperlipidemia’s.136,137,138,139 However, there is not a previous approach to relate these 
genetic variants with CRC risk, except for APOE93, PPARG140 and PON162 polymorphisms.  
Most tissues are not capable to catabolize cholesterol, when this occur the non-
catabolized cholesterol returns into the liver. In liver cholesterol can be then secreted into 
bile, directly or after conversion to bile acids (BAs). This pathway might stimulate BAs 
secretion into the colon. BAs are cholesterol metabolites and are classified in two groups: 
primary BAs (BAs I) that are synthesized in liver bias cholesterol; and secondary BAs (BAs 
II) that are produced by intestinal bacteria bias Bas I. In colonic cells, BAs promotes 
digestion assuring fat solubilization and emulsification (Figure 24). After meal, BAs and 
their conjugates are delivered in duodenum to facilitate fats and vitamins digestion and 
absorption by the intestine throughout enterocyte barrier. In ileum and colon, the 
majority of BAs (95%) is reabsorbed into liver and then recycled (they can be excreted 20-
40 times during digestion). Nevertheless, the excess of BAs can be eliminated by the 
feces, namely BAs II.130,131,141,142,143  
Colon cells exposure to high physiologic BAs levels induces reactive oxygen species 
(ROS) formation and, consequently, cells undergo oxidative stress that could lead to DNA 
damage and chromosome abnormalities (Figure 23).144,128 As result of DNA damage, 
apoptosis is inducted by p53 signaling pathway activation. P53 is a crucial tumour 
suppressor involved in several cellular responses, such as differentiation, senescence, 
DNA repair and angiogenesis inhibition.145 However, a prolonged exposure to high BAs 
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levels of normal cells and the replication of cells with DNA damage originate mutant cells 
clusters. 128,136,146  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Diagram of SCA progression and development from increase of bile acid levels caused 
by genetic factors (SNP’s) and high fat diet. Adapted from references144,128 
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In long-term, persistent colonic epithelial cells exposure to high BAs physiologic 
concentration appears to favor survival of the cells that are resistant to BAs apoptosis 
induction (resistance to p53 signaling pathway), leading to their proliferation (Figure 23). 
BAs II have influence in most genes involved in inflammation processes, angiogenesis, 
epithelial barrier function, oxidative stress, apoptosis, cell proliferation/cell cycle/DNA 
repair, membrane transport and ubiquitin-proteasome pathway. These mechanisms lead 
to secondary mutations formation that are involved in colorectal adenomas 
development.128,146,129, 144,145 
APOA1 -75 G>A, APOB R3500Q, APOC3 C3175G, APOC3 T3206G, APOE 
Cys112/158Arg, CETP G279A, CETP R451Q, PON1 Q192R, NPY Leu7Pro, PPARG Pro12Ala 
polymorphisms have not their role in BAs II cancer mechanisms well clarified although 
there are some evidences that associate these variants with cholesterol and/or 
triglycerides metabolism that are directly involved in BAs metabolic regulation. 
55,56,57,58,59,60,61,62,63  In this work we tried to make a connection between lipid metabolism 
gene polymorphisms, diet cholesterol/BAs equilibrium, adenomas development and SCA 
risk (Figure 23). 
 
4.1. Influence of common lipid metabolism genes polymorphism 
among SCA and controls 
 
Lipid transport and metabolism genes studied are involved in essentials 
mechanisms of SCA development and progression. This hypothesis is corroborated with 
the results of this work, since it was found a high correlation between mutant alleles, 
APOA1 -75A, APOB 3500Q, CETP 279A, CETP 451Q, APOC3 3175G, PON1 192R, NPY 7Pro 
and PPARG 12Ala, and SCA prevalence. However, APOE gene and APOC3 T3206G variant 
only demonstrated a significate differences in their genotypes. All these genes are linked 
to dyslipidemia. Dyslipidemias are usually associated with intestinal mucosal exposure to 
high lipids concentrations, including cholesterol and BAs II.139,9  
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4.1.1. Influence of APOA1 polymorphism in SCA 
 
APOA1 is the major HDL-C protein component and plays a crucial role in reverse 
cholesterol transport, promoting cholesterol efflux from tissues into liver. Also, it is a 
cofactor for LCAT which is responsible for most plasma cholesteryl esters formation.68,47 
Defects in APOA1 gene are associated with HDL alterations, bias influence of 
apolipoprotein expression levels. APOA1 -75A allele is linked to increase APOA1 gene 
transcription levels, thus individuals carrying this allele have higher APOA1 and HDL-C 
concentrations. However, this relationship with APOA1 and HDL-C levels is controversial 
as indicated by inconsistencies in well-designed studies. Danek et al,65 suggest that 
APOA1 -75A allele does not directly affect APOA1 gene transcriptional efficiency.65 Other 
studies have shown that APOA1 -75AA genotype was associated with type 2 diabetes 
increased risk, on the contrary APOA1 -75GG genotype has been found to be strongly 
associated with myocardial infarction, hypertension and metabolic syndromes. This 
finding suggest that APOA1 -75A allele carriers have a lower lipid absorption in intestinal 
mucosa.55 Several studies revealed essential APOA1 roles in inflammation, tumour 
growth, angiogenesis, invasion and metastasis. The increased levels of APOA1 in patients 
with adenocarcinomas were associated with enhanced tumour growth and lymphatic 
invasion. Hamrita et al,69 show that APOA1 -75 G>A have an important role  in 
susceptibility to breast cancer metastases occurrence.69 Nevertheless, there is no 
association yet between APOA1 -75 G>A variant and CRC risk, since this polymorphism 
has been only associated with cardiovascular events .65 
Although most studies are contradictory, in this work we found that APOA1 -75A 
allele and APOA1 -75AA genotype carriers have a strong association with SCA prevalence. 
APOA1 -75A mutation appears to be associated with lipids low absorption by enterocytes 
and with increased fats accumulation in colon and rectum. Also, APOA1 -75A is correlated 
with higher HDL and low LDL blood levels7, and since HDL transport to hepatocytes has 
showed an increase bile acid synthesis,147 its association with an increased risk of SCA is 
justified. Moreover, there are also evidences that this variant could manipulate BAs II and 
inflammation levels,69 mechanisms correlated with p53 inhibition and SCA risk increase.  
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4.1.2. Influence of APOB polymorphism in SCA 
 
APOB is the main apolipoprotein of chylomicrons, VLDL, IDL, and LDL particles, 
which allows lipid transport to all human tissues. APOB-100 isoform is express in liver and 
is an essential component for VLDL synthesis and secretion, also can acts as a ligand for 
LDL recognition and catabolism by its receptor. 47,80 Mutation in APOB-100 cause changes 
in LDL and VLDL synthesis and transport. Several finding have shown that APOB R3500Q 
variant change protein functional activity, decreasing its binding LDL receptor, slowing 
LDL particles clearance and leading LDL-C blood accumulation. All APOB R3500Q (G>A) 
genotypes presented statistically significate differences among SCA and control subjects, 
but heterozygous (GA) and mutate homozygous (AA) were more frequent among SCA 
subjects. Thus, APOB 3500Q (A) allele appears to be a potential SCA risk factor. A possible 
explanation for these findings is the lipids accumulation in colon, including cholesterol 
and BAs II, which contributes to ROS and oxidative stress increase.  
Our results are in accordance with a study conducted in vitro in rat hepatocytes 
suggesting that 3500A allele, although being associated to LDL-C increase in circulation, 
duo to its LDL-R low affinity, also decrease triglycerides and LDL-C transport to liver or 
colon for other tissues. Contrarily, wt homozygous, APOB 3500RR suggested has a 
protective effect in SCA.148 Furthermore, APOB 3500QQ carriers normally are 
hypercholesterolemic, however TC, LDL-C and TG concentrations are lower in Familial 
defective apolipoprotein B-100 (FDB) than familial hypercholesterolemia (FH),56 and 
lower plasma lipoprotein levels in FDB can partially be caused by an increased uptake of 
VLDL remants.81 Also, APOB-100 secretion have effects on BAs synthesis, being this fact 
demonstrated in a study realized in HepG2 cells. The decrease of APOB-100 and the 
increase of APOA1 concentrations are normally accompanied by BAs synthesis 
increment.147 Our work demonstrated that APOB 3500Q variant is associated SCA, since 
this mutation increases bile acid synthesis and its accumulation in colon and rectum 
disrupting p53 pathway.  
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4.1.3. Influence of APOC3 polymorphisms in SCA 
 
APOC3 is a fundamental protein in triglycerides lipolysis inhibition, through LPL 
and hepatic TG lipase activity inhibition. This protein is a component of chylomicron and 
VLDL, that acts as a major triglycerides catabolism regulator, resulting in a diminished 
catabolic rate and in a reduced chylomicrons and VLDL clearance.57,47,87,88 APOC3 activity 
is affected by two mutations in APOC3 gene, C3175G and T3206G. In this study, 
heterozygous and mutant homozygotes of APOC3 3175 showed a strong association with 
SCA, which can be explained by their higher APOC3 activity when compared with wt 
genotype. Although this mutation has not been yet related with CRC, several studies 
demonstrate its association with cardiovascular diseases (CVD) and dyslipidemias. 
Numerous studies has investigated these polymorphism associations with APOC3 and 
lipid plasma levels. Accordingly, some studies demonstrated that the carriers APOC3 
3175G mutant allele is associated with higher APOC3, TG, TC, and LDL-C plasma levels and 
lower HDL-C levels.57,89 These low HDL-C plasma levels can explain the prevalence of this 
variant in SCA subjects, suggesting that it could be accumulating in colon.  
In this work, APOC3 T3206G variant seemed to influences SCA development. 
APOC3 3206GG mutant genotype showed a strong association with SCA risk increase, 
while APOC3 3206TG genotype showed a protective effect for SCA. APOC3 3206GG 
genotype has been associated with lower TC, HDL-C and LDL-C plasma levels, that could 
explain its prevalence among SCA subjects,57,89 since these elements lower plasma levels 
are associated with higher lipid excretion by feces, resulting in lipids absorption 
decrease.11,12,149 These two APOC3 polymorphisms appear to have a similar effect, 
although by different pathways, on SCA susceptibility increasing its risk by increasing 
intestinal lipid accumulation and excretion through feces.   
 
4.1.4. Influence of APOE polymorphisms in SCA 
 
APOE plays an important role in lipid metabolism by mediating lipoprotein 
particles binding to LDL and APOE receptors. In this work, APOE E3/E4 genotype showed a 
negative association with SCA prevalence. This can be explain by APOE’s role in entero-
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hepatic metabolism, influencing fecal bile acids concentration, which may participate in 
CRC adenocarcinomas formation, essentially in proximal colon, where they are in direct 
contact with the mucous membrane. APOE E4/E4 genotype seemed to be a protective 
factor in SCA, being only present in control subjects. APOE*4 allele presences is 
associated with lower concentrations secondary bile acids in gastrointestinal tract.41,58,93  
It suggest that APOE E4 allele presence results in higher cholesterol absorption and lower 
intestinal accumulation.41,58,93  APOE E4/E4 protective effect is confirm by several studies 
realized with CRC patients.41,58,93 Nevertheless, APOE E4 allele has been associated with 
increased risk in other diseases, including hypertension, coronary disease, breast cancer 
and Alzheimer.90,91   
 
4.1.5. Influence of CETP polymorphisms in SCA 
 
CETP facilitates cholesteryl esters transfer from HDL to APOB-containing 
lipoproteins in exchange of triglycerides.51 Furthermore, CETP plays an important role in 
reverse cholesterol transport pathway. In this work, CETP 279AA, mutant variant, and 
CETP 279GA genotypes showed significant associations with SCA occurrence. A previous 
study, in children from families with cardiovascular system diseases history, showed a 
correlation between CETP 279A allele presence, CETP lower activity and higher HDL 
cholesterol value. Moreover, this study also showed that CETP 279GA and CETP 279AA 
are linked to TG, TC, LDL-C, VLDL-C and APOB levels decrease, on other hand they are 
associated with APOA1 increase.100 However there are no studies that relate this variant 
with CRC, nevertheless cardioprotective effects are normally associated with a lipid 
absorption reduction in gut and consequently increase BAs II levels within intestinal 
mucosa.  
CETP gene has other genetic variant linked to CRC risk, R451Q (G>A). A study 
conducted on population of Northern Finland showed that increase in this mutation 
frequency was linked to CETP activity increase and lower cholesterol plasma levels.59   
This speculation may explain our results, in which CETP 451AA (QQ, mutant genotype) 
was prevalent between SCA subjects. Like CETP G279A there are no studies that relate 
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CETP R451Q with CRC, nevertheless, lower cholesterol serum levels associated with a 
decrease in lipid absorption by colon epithelium could explained this positive association 
among SCA and CETP variants. 
 
4.1.6. Influence of NPY polymorphism in SCA 
 
NPY is a neural transmitter that regulates food intake and energy storage. Also, it 
may regulate serum free fatty acid (FFA) levels. NPY Leu7pro polymorphism has been 
associated with serum TC and LDL-C regulation. NPY 7Pro allele carriers have lower FFA 
levels and higher lipid oxidation rates than NPY 7Leu allele carriers, however 
heterozygotes seemed to have a lower lipid oxidation rates.52 This evidences could 
explain our results, since every genotypes exhibited statistically significate differences, 
being NPY 7ProLeu o and 7ProPro mutated genotypes associated with SCA risk, whereas 
7LeuLeu (wt genotype) appears to have a protective role in SCA. Although NPY 
polymorphisms has not yet been studied in CRC, our results are in accordance with this 
variant role in NPY activity, since it mutated form increases NPY activity increasing food 
intake, dropping FFA levels and increasing lipid oxidation rates,132,25 variables directly 
associated with CRC risk. 
 
4.1.7. Influence of PON1 polymorphism in SCA 
 
PON1 has a crucial role in HDL antioxidant activity by protecting LDL against lipid 
peroxidation. PON1 protein in plasma is co-associated with HDL, playing an 
atheroprotective effect. A study realized in mice demonstrate that increase bile acids 
alter PON1 hepatic expression, leading to PON1 repression and increasing inflammatory 
cytokines expression and secretion.119 Genetic variations in antioxidant enzymes may 
influence colonic expression pattern and modulate colon epithelium cells ability to handle 
with metabolic damage and alterations. PON1 Q192R (A>G) polymorphism is associated 
with altered PON1 concentrations. In this work, PON1 192A (Q) allele demonstrated to 
have a protective role in SCA and PON1 192G (R) allele and PON1 192AG (QR) genotype 
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showed an association with SCA risk. However, a study reported the opposite effect being  
PON1 192G (R) mutated allele associated with protection and the wt associated with 
risk.62 Nevertheless, other study demonstrated that PON1 plasma concentration decrease 
drastically in CRC, comparatively with controls subjects, being is low activity associated 
with tumourgenesis.118 PON1 in normal conditions have a protective role against 
oxidative damage and lipid peroxidation on colon cells.115,150 Thus, the incidence of this 
polymorphism causes a higher susceptibility to lipid oxidation exposure and ROS 
accumulation in epithelium colon, increasing the likelihood of SCA prevalence.  
 
4.1.8. Influence of PPARG polymorphism in SCA 
 
PPARG regulate essential genes in cell differentiation, several metabolic 
processes, such as lipid and glucose homeostasis, and oxidative processes.151 Moreover, it 
plays roles in lipid storage, inflammation and energy metabolism. PPARG gene exhibits 
different expression in normal colonic mucosa, colorectal adenocarcinomas and colon 
cancer cell lines.  PPARG 12Ala (mutated form) polymorphism is related with PPARG 
decrease activity. In this work, PPARG 12Ala mutated allele and genotype showed an 
association with SCA risk. These results are in agreement with the literature, a study 
realized in CRC patients demonstrated that this mutation can have an protector effect in 
colon, but presents risk in rectum.124 Thus, the incidence of this polymorphism causes a 
higher susceptibility to lipid oxidation and ROS accumulation increasing the SCA risk. 
 
4.2. Influence of lipid transport and metabolism genes 
polymorphisms in SCA 
 
Most of the polymorphisms approached in this work seemed to influence SCA 
apparently by lipids and triglycerides levels increase and/or oxidation rates raise. A 
disturbance in genes involved in lipid metabolism and transport, may cause less lipids 
absorption by colonic mucosa. This pathway also impairs enterohepatic cycle, which has 
an important role in bile acids metabolism, increasing BAs I production and consequently 
increases BAs II formation. Prolonged exposure of colonic epithelium to high BAs 
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concentrations rises: lipid peroxidation; ROS production; cell membrane rupture; DNA 
damage induced by mitochondria; and mutation levels.128,144 This prolonged exposure also 
reduction cells apoptosis capacity normally induced by cellular genomic instability (Figure 
23), increasing cell membrane permeability, leading to colonic epithelium destruction. 
Consequently, these elements induce cell proliferation by activating epidermal growth 
factor receptor (EGFR) and others growth factors.146 Furthermore, BAs induced 
hyperproliferation can occur through the activity of protein kinase C (PKC), which can be 
activated by EGFR downstream or by membrane perturbation. ROS/RNS production has 
several consequences, such as: mitochondrial membrane alterations, high mutations 
occurrence levels and apoptosis intrinsic pathway activation (by tumour suppressor p53). 
146 This pathway, leads to cytochrome C release and cytosolic caspases stimulation. 
Furthermore, BAs can also induce K-ras mutations, and micronuclei aneuploidy 
formation. All of these processes, induced by BAs, are described to influence positively 
tumourigenesis process, namely SCA.128,129,145,146   
4.3. Gender 
 
It appeared to be no link between any polymorphic variants and gender, since 
there was no significant differences in allele and genotype distributions among both 
genders. These results can be possibly explained by the fact that the majority of our 
samples are composed by male subjects (75% versus 25%). 
 
4.4. Distinction between colonic and rectal adenocarcinomas 
 
Colon cells are subject to a high cell renewal.131 Colonic epithelium persistent 
exposure to elevated lipid concentrations and bile acids, together with genetic factors, 
leads to intestinal adenomas formation.128,139 BAs effects varies with intestinal location, 
colon or rectum. This could be explained by BAs I and BAs II synthetizes location, in liver 
and colon, respectively.131 Also, BAs II seem to have a greater carcinogenic promotion 
among rectum tissue. Therefore, significant differences between rectal and colon 
carcinomas with respect to genetic features have been reported.152 
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SCA subjects in this study were stratified according to primary tumour location: 
colonic or rectal. This work showed that PPARG 12Ala polymorphism was associated to 
rectum tumour. This result is in accordance with the majority of studies, although not 
significant, that reported that PPARG 12AlaAla is associated with increased rectum cancer 
risk.63,124 In addition, also was reported that PPARG 12Ala variant is a protective factor in 
colon cancer. Results from this study showed that APOC3 3206TG genotype was 
associated with colon tumour. This result can be explained by expression level among 
colon and rectum, since APOC3 gene has a major expression in colon normal tissue.153  
Moreover, APOB 3500GA and CETP 279AA (mutant) genotypes shows a stronger 
association with rectum tissue. Sniderman et al.147 demonstrate that decrease APOB 
levels was associated with bile acids formation that it has a major influence in rectum, 
suggesting an implication in CRC risk.147 One study showed that CETP secretion is 
regulated by fatty acids absorption into Caco-2 cells.154 CETP 279A variant is associated 
with CETP decreased activity, which is also decreased in patients with cholestasis 
(pathology associated with nutritional deficiencies due to inadequate dietary intake, 
maldigestion, malabsorption and/ or poor metabolism of nutrients).154 This finding 
suggests that CETP have a similar mechanism in SCA and cholestasis, which proposes 
enterohepatic recycling impairment causing fats and bile acids accumulation in liver and 
intestine, increasing their excretion through rectum.131,154 Again prolonged exposure to 
fats can increase ROS and consequential cells damaging. This work reinforces that there 
are some susceptibility differences according to tumour primary localization.  
4.5. Future perspectives  
 
In future could be fundamental gathered investigations about fat and BAs II levels 
in feces to certificate the association between SCA prevalence and increased lipid and 
ROS levels and excretion among gastrointestinal tract. Also is essential to get CRC 
patient’s HDL-C, LDL-C, TG and TC plasma levels and relate their decrease with the 
increase of lipid levels in feces. Finally, is important to relate the polymorphisms studied 
with their gene and protein expressions, determining if occur loss or gain-of-function, and 
allowing the clarification of polymorphisms role in SCA. 
Common lipid metabolism genes polymorphisms and SCA risk | Pandeirada R. 2015   87  
 
4.6. Study limitations 
 
There may be several possible mechanisms underlying all association studies, such 
as, the results from interaction of both environmental and genetic factors, which can be 
responsible for analysis default. Present study sample size (68 SCA and 100 controls) may 
not be large enough to detect small effect from low penetrance mutations. The combined 
effect of multiple genes/mutations can provide more reliable information for genetic 
contribution to SCA risk. We cannot completely exclude the effects from other conditions 
(i.e. weight, gender, diet type, etc.) and residual confounding attributable to the 
measurement error (namely, unicentric characters, takes medication, lack of assess of 
diet in takes, etc…). It is essential a large approach study with large sample size to confirm 
our outcomes. Still, the present study provides preliminary evidence that APOA1, APOB, 
APOC3, CETP, NPY, PON1 and PPARG variants, may contribute to the SCA risk in 
Portuguese population, and may be useful tools in the study of this multifactorial 
disorder. 
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Chapter V 
Conclusions 
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5. Conclusion 
 
Observations and results founded in this study show that polymorphisms from 
APOA1, APOB, APOC3, CETP, NPY, PON1 and PPARG genes were associated with increased 
risk development of SCA. This leads to believe that individuals carrying these genetic 
variants may differently susceptible to SCA.  Common APOE gene polymorphism revelled 
has a protective effect in SCA. APOA1, APOB, APOC3, CETP, NPY, PON1 and PPARG 
proteins, whose role is essential in lipid transport and metabolism and also in antioxidant 
properties (PON1 and PPARG), when altered can influenced adenocarcinoma 
development process in colon and rectum tissues. Alterations in genes encoding proteins 
involved in lipid metabolism and transport contribute their functions deregulation. There 
are several mechanisms that may explain how this change may affect CRC risk, namely: 
changes in enterohepatic cycle; intestinal absorption decreased (due to alterations in 
transport); and gastrointestinal tract accumulation of lipid and toxic bile acids. 
Consequently, these changes cause ROS formation, DNA damage, apoptosis induction and 
new mutations appearance. Therefore, it is supposed that common mutant alleles from 
APOA1, APOB, APOC3, CETP, NPY, PON1 and PPARG genes (that influence lipid 
metabolism and transport) can be associated with an increased SCA risk. Thus, these 
common polymorphisms appears be prospective biomarkers to SCA susceptibility. Most 
of the results described in this study have never been described and is fundamental 
further study for obtaining more illuminating findings. Finally, in this study it was also 
highlighted that primary tumour localization may be conditioned by APOB, APOC3, CETP 
and PPARG polymorphisms. 
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7. Appendix  
 
Table 20. Hardy-Weinberg Equilibrium to common lipid metabolism genes polymorphisms in 
control population. 
 
 
Hardy-Weinberg Equilibrium 
SNP 
 
Controls 
χ2 P-value 
APOA1 -75G>A 0,99 0,26 
APOB R3500Q 1 0,96 
APOC3 C3175G 0,97 0,2 
APOC3 T3206G 0,86 0,02 
APOE Cys112Arg 1 0,84 
APOE Arg158Cys 1 0,78 
CETP G279A 0,91 0,33 
CETP R451Q 0,97 0,6 
NPY Leu7Pro 1 0,84 
PON1 Q192R 0,98 0,03 
PPARG Pro12Ala 1 0,45 
 
 
